UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
For the quarterly period ended
Commission file number:
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation) | (IRS Employer Identification No.) | |
(Address of Principal Executive Offices) | (Zip Code) | |
(Registrant’s Telephone Number, Including Area Code) ( Not Applicable | ||
(Former Name or Former Address, if Changed Since Last Report) Securities registered pursuant to Section 12(b) of the Act: | ||
Title of each class |
| Trading Symbol(s) |
| Name of each exchange on which registered |
Note: The common stock of the Registrant is also traded on the SWX Swiss Exchange.
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.:
Accelerated filer ☐ | ||
Non-accelerated filer ☐ | Smaller reporting company | |
Emerging growth company |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes
Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.
Class | Outstanding at June 30, 2021 | |
Common Stock, $0.01 par value per share |
3M COMPANY
Form 10-Q for the Quarterly Period Ended June 30, 2021
TABLE OF CONTENTS | BEGINNING | |
3 | ||
Index to Financial Statements: | ||
3 | ||
4 | ||
5 | ||
6 | ||
7 | ||
7 | ||
9 | ||
12 | ||
12 | ||
14 | ||
16 | ||
Note 7. Supplemental Equity and Comprehensive Income Information | 16 | |
20 | ||
20 | ||
21 | ||
21 | ||
22 | ||
29 | ||
31 | ||
49 | ||
52 | ||
Management’s Discussion and Analysis of Financial Condition and Results of Operations | 54 | |
Index to Management’s Discussion and Analysis: | ||
54 | ||
63 | ||
65 | ||
70 | ||
Cautionary Note Concerning Factors That May Affect Future Results | 76 | |
77 | ||
77 | ||
78 | ||
78 | ||
82 | ||
83 | ||
83 | ||
83 | ||
83 |
2
3M COMPANY
FORM 10-Q
For the Quarterly Period Ended June 30, 2021
PART I. Financial Information
Item 1. Financial Statements.
3M Company and Subsidiaries
Consolidated Statement of Income
(Unaudited)
| Three months ended |
| Six months ended |
| |||||||||
June 30, | June 30, | ||||||||||||
(Millions, except per share amounts) |
| 2021 |
| 2020 |
| 2021 | 2020 |
| |||||
Net sales | $ | | $ | | $ | | $ | | |||||
Operating expenses | |||||||||||||
Cost of sales |
| |
| |
| |
| | |||||
Selling, general and administrative expenses |
| |
| |
| |
| | |||||
Research, development and related expenses |
| |
| |
| |
| | |||||
Gain on sale of businesses | — | ( | — | ( | |||||||||
Total operating expenses |
| |
| |
| |
| | |||||
Operating income |
| |
| |
| |
| | |||||
Other expense (income), net |
| |
| |
| |
| | |||||
Income before income taxes |
| |
| |
| |
| | |||||
Provision for income taxes |
| |
| |
| |
| | |||||
Income of consolidated group | | | | | |||||||||
Income (loss) from unconsolidated subsidiaries, net of taxes | | — | | — | |||||||||
Net income including noncontrolling interest | | | | | |||||||||
Less: Net income (loss) attributable to noncontrolling interest |
| |
| ( |
| |
| ( | |||||
Net income attributable to 3M | $ | | $ | | $ | | $ | | |||||
Weighted average 3M common shares outstanding — basic |
| |
| |
| |
| | |||||
Earnings per share attributable to 3M common shareholders — basic | $ | | $ | | $ | | $ | | |||||
Weighted average 3M common shares outstanding — diluted |
| |
| |
| |
| | |||||
Earnings per share attributable to 3M common shareholders — diluted | $ | | $ | | $ | | $ | | |||||
The accompanying Notes to Consolidated Financial Statements are an integral part of this statement.
3
3M Company and Subsidiaries
Consolidated Statement of Comprehensive Income
(Unaudited)
| Three months ended |
| Six months ended | |||||||||
June 30, | June 30, | |||||||||||
(Millions) |
| 2021 |
| 2020 |
| 2021 |
| 2020 | ||||
Net income including noncontrolling interest | $ | | $ | | $ | | $ | | ||||
Other comprehensive income (loss), net of tax: | ||||||||||||
Cumulative translation adjustment |
| |
| |
| ( |
| ( | ||||
Defined benefit pension and postretirement plans adjustment |
| |
| |
| |
| | ||||
Cash flow hedging instruments |
| ( |
| ( |
| |
| | ||||
Total other comprehensive income (loss), net of tax |
| |
| |
| |
| ( | ||||
Comprehensive income (loss) including noncontrolling interest |
| |
| |
| |
| | ||||
Comprehensive (income) loss attributable to noncontrolling interest |
| — |
| |
| ( |
| | ||||
Comprehensive income (loss) attributable to 3M | $ | | $ | | $ | | $ | | ||||
The accompanying Notes to Consolidated Financial Statements are an integral part of this statement.
4
3M Company and Subsidiaries
Consolidated Balance Sheet
(Unaudited)
| June 30, |
| December 31, |
| |||
(Dollars in millions, except per share amount) |
| 2021 |
| 2020 |
| ||
Assets | |||||||
Current assets | |||||||
Cash and cash equivalents | $ | | $ | | |||
Marketable securities — current |
| |
| | |||
Accounts receivable — net of allowances of $ |
| |
| | |||
Inventories | |||||||
Finished goods |
| |
| | |||
Work in process |
| |
| | |||
Raw materials and supplies |
| |
| | |||
Total inventories |
| |
| | |||
Prepaids | | | |||||
Other current assets |
| |
| | |||
Total current assets |
| |
| | |||
Property, plant and equipment |
| |
| | |||
Less: Accumulated depreciation |
| ( |
| ( | |||
Property, plant and equipment — net |
| |
| | |||
Operating lease right of use assets | | | |||||
Goodwill |
| |
| | |||
Intangible assets — net |
| |
| | |||
Other assets |
| |
| | |||
Total assets | $ | | $ | | |||
Liabilities | |||||||
Current liabilities | |||||||
Short-term borrowings and current portion of long-term debt | $ | | $ | | |||
Accounts payable |
| |
| | |||
Accrued payroll |
| |
| | |||
Accrued income taxes |
| |
| | |||
Operating lease liabilities — current | | | |||||
Other current liabilities |
| |
| | |||
Total current liabilities |
| |
| | |||
Long-term debt |
| |
| | |||
Pension and postretirement benefits |
| |
| | |||
Operating lease liabilities | |
| | ||||
Other liabilities |
| |
| | |||
Total liabilities | $ | | $ | | |||
Commitments and contingencies (Note 14) | |||||||
Equity | |||||||
3M Company shareholders’ equity: | |||||||
Common stock par value, $ | $ | | $ | | |||
Shares outstanding - June 30, 2021: | |||||||
Shares outstanding - December 31, 2020: | |||||||
Additional paid-in capital |
| |
| | |||
Retained earnings |
| |
| | |||
Treasury stock, at cost: |
| ( |
| ( | |||
Shares at June 30, 2021: | |||||||
Shares at December 31, 2020: | |||||||
Accumulated other comprehensive income (loss) |
| ( |
| ( | |||
Total 3M Company shareholders’ equity |
| |
| | |||
Noncontrolling interest |
| |
| | |||
Total equity | $ | | $ | | |||
Total liabilities and equity | $ | | $ | | |||
The accompanying Notes to Consolidated Financial Statements are an integral part of this statement.
5
3M Company and Subsidiaries
Consolidated Statement of Cash Flows
(Unaudited)
| Six months ended | |||||
June 30, | ||||||
(Millions) |
| 2021 |
| 2020 | ||
Cash Flows from Operating Activities | ||||||
Net income including noncontrolling interest | $ | | $ | | ||
Adjustments to reconcile net income including noncontrolling interest to net cash provided by operating activities | ||||||
Depreciation and amortization |
| |
| | ||
Company pension and postretirement contributions |
| ( |
| ( | ||
Company pension and postretirement expense |
| |
| | ||
Stock-based compensation expense |
| |
| | ||
Gain on sale of businesses | — | ( | ||||
Deferred income taxes |
| |
| | ||
Changes in assets and liabilities | ||||||
Accounts receivable |
| ( |
| | ||
Inventories |
| ( |
| ( | ||
Accounts payable |
| |
| ( | ||
Accrued income taxes (current and long-term) |
| ( |
| | ||
Other — net |
| ( |
| ( | ||
Net cash provided by (used in) operating activities |
| |
| | ||
Cash Flows from Investing Activities | ||||||
Purchases of property, plant and equipment (PP&E) |
| ( |
| ( | ||
Proceeds from sale of PP&E and other assets |
| |
| | ||
Acquisitions, net of cash acquired |
| — |
| ( | ||
Purchases of marketable securities and investments |
| ( |
| ( | ||
Proceeds from maturities and sale of marketable securities and investments |
| |
| | ||
Proceeds from sale of businesses, net of cash sold |
| — |
| | ||
Other — net |
| |
| | ||
Net cash provided by (used in) investing activities |
| ( |
| | ||
Cash Flows from Financing Activities | ||||||
Change in short-term debt — net |
| |
| ( | ||
Repayment of debt (maturities greater than 90 days) |
| ( |
| ( | ||
Proceeds from debt (maturities greater than 90 days) |
| |
| | ||
Purchases of treasury stock |
| ( |
| ( | ||
Proceeds from issuance of treasury stock pursuant to stock option and benefit plans |
| |
| | ||
Dividends paid to shareholders |
| ( |
| ( | ||
Other — net |
| ( |
| ( | ||
Net cash provided by (used in) financing activities |
| ( |
| ( | ||
Effect of exchange rate changes on cash and cash equivalents |
| ( |
| ( | ||
Net increase (decrease) in cash and cash equivalents |
| |
| | ||
Cash and cash equivalents at beginning of year |
| |
| | ||
Cash and cash equivalents at end of period | $ | | $ | | ||
The accompanying Notes to Consolidated Financial Statements are an integral part of this statement.
6
3M Company and Subsidiaries
Notes to Consolidated Financial Statements
(Unaudited)
NOTE 1. Significant Accounting Policies
Basis of Presentation
The interim consolidated financial statements are unaudited but, in the opinion of management, reflect all adjustments necessary for a fair statement of the Company’s consolidated financial position, results of operations and cash flows for the periods presented. These adjustments consist of normal, recurring items. The results of operations for any interim period are not necessarily indicative of results for the full year. The interim consolidated financial statements and notes are presented as permitted by the requirements for Quarterly Reports on Form 10-Q. This Quarterly Report on Form 10-Q should be read in conjunction with the Company’s consolidated financial statements and notes included in its Annual Report on Form 10-K.
Effective in the first quarter of 2021, 3M made the following changes. Information provided herein reflects the impact of these changes for all periods presented.
| ● | Change in accounting principle for net periodic pension and postretirement plan cost. See below for additional information. |
| ● | Change in measure of segment operating performance used by 3M’s chief operating decision maker—impacting 3M’s disclosed measure of segment profit/loss (business segment operating income). See additional information in Note 16. |
| ● | Change in alignment of certain products within 3M’s Consumer business segment—creating the Consumer Health and Safety Division. See additional information in Note 16. |
Change in Accounting Principle for Determining Net Periodic Pension and Postretirement Plan Cost
In the first quarter of 2021, 3M changed the method it uses to calculate the market-related value of fixed income securities included in its pension and other postretirement plan assets. The market-related value is used to determine the expected return on plan assets and the amortization of net unamortized actuarial gains or losses expense components of net periodic benefit cost. The Company previously used the calculated value approach for all plan assets, deferring over three years the impact on these amounts of asset gains or losses that differed from expected returns. 3M changed to the fair value approach for calculating market-related value for the fixed income class of plan assets, which does not involve deferring the impact of excess plan asset gains or losses in the determination of these two components of net periodic benefit cost. 3M considers the use of the fair value approach preferrable to the calculated value approach as it results in a more current reflection of impacts of changes in value of these plan assets in the determination of net periodic benefit cost. Additionally, given the plans’ liability-driven investment strategy whereby the changes in value of the fixed income plan assets should offset changes in the value of the plans’ liabilities, this approach more closely aligns the expected return on plan assets expense component with the value reflected in the plans’ funded status. This change was applied retrospectively to all periods presented within 3M’s financial statements. The change did not impact consolidated operating income or net cash provided by operating activities but did impact the previously reported portion of pension and postretirement net periodic benefit cost (benefit) that was included within non-operating other expense (income) along with related consolidated income items such as net income and earnings per share. Other impacts included related changes to previously reported consolidated other comprehensive income, retained earnings, accumulated other comprehensive income (loss), and associated line items within the determination of net cash provided by operating activities. For classes of plan assets other than fixed income investments, the Company continues to use the calculated value approach to determine their market-related value.
7
The adoption of this change impacted previously reported amounts included herein as indicated in the tables below.
Consolidated Statement of Income | Three months ended | Six months ended | ||||||||||
June 30, 2020 | June 30, 2020 | |||||||||||
Under Prior |
| Under Prior | ||||||||||
(Millions, except per share amounts) | Method | As Adjusted | Method | As Adjusted | ||||||||
Other expense (income), net | $ | | $ | | $ | | $ | | ||||
Income before income taxes | $ | | $ | | $ | | $ | | ||||
Provision for income taxes | | | | | ||||||||
Income of consolidated group | $ | | $ | | $ | | $ | | ||||
Net income including noncontrolling interest | $ | | $ | | $ | | $ | | ||||
Net income attributable to 3M | $ | | $ | | $ | | $ | | ||||
Earnings per share attributable to 3M common shareholders — basic | $ | | $ | | $ | | $ | | ||||
Earnings per share attributable to 3M common shareholders — diluted | $ | | $ | | $ | | $ | | ||||
Consolidated Statement of Comprehensive Income | Three months ended | Six months ended | ||||||||||
June 30, 2020 | June 30, 2020 | |||||||||||
Under Prior |
| Under Prior | ||||||||||
(Millions) | Method | As Adjusted | Method | As Adjusted | ||||||||
Net income including noncontrolling interest | $ | | $ | | $ | | $ | | ||||
Other comprehensive income (loss), net of tax: | ||||||||||||
Defined benefit pension and postretirement plans adjustment | $ | | $ | | $ | | $ | | ||||
Total other comprehensive income (loss), net of tax | $ | | $ | | $ | ( | $ | ( | ||||
Comprehensive income (loss) including noncontrolling interest | $ | | $ | | $ | | $ | | ||||
Comprehensive income (loss) attributable to 3M | $ | | $ | | $ | | $ | | ||||
Consolidated Balance Sheet | As of December 31, 2020 | |||||
Under Prior | ||||||
(Millions) | Method | As Adjusted | ||||
Retained earnings | $ | | $ | | ||
Accumulated other comprehensive income (loss) | $ | ( | $ | ( | ||
Consolidated Statement of Cash Flows | Six months ended | ||||||
June 30, 2020 | |||||||
Under Prior | |||||||
(Millions) | Method | As Adjusted | |||||
Net income including noncontrolling interest | $ | | $ | | |||
Company pension and postretirement expense | $ | | $ | | |||
Other — net | $ | ( | $ | ( | |||
The cumulative adjustment as of January 1, 2020, the beginning of the earliest period presented in the consolidated financial statements included herein, was a $
Earnings Per Share
The difference in the weighted average 3M shares outstanding for calculating basic and diluted earnings per share attributable to 3M common shareholders is a result of the dilution associated with the Company’s stock-based compensation plans. Certain options outstanding under these stock-based compensation plans were not included in the computation of diluted earnings per share attributable to 3M common shareholders because they would have had an anti-dilutive effect (
8
three months ended June 30, 2020;
Earnings Per Share Computations
| Three months ended |
| Six months ended | |||||||||
June 30, | June 30, | |||||||||||
(Amounts in millions, except per share amounts) |
| 2021 |
| 2020 |
| 2021 |
| 2020 | ||||
Numerator: | ||||||||||||
Net income attributable to 3M | $ | | $ | | $ | | $ | | ||||
Denominator: | ||||||||||||
Denominator for weighted average 3M common shares outstanding – basic |
| |
| |
| |
| | ||||
Dilution associated with the Company’s stock-based compensation plans |
| |
| |
| |
| | ||||
Denominator for weighted average 3M common shares outstanding – diluted |
| |
| |
| |
| | ||||
Earnings per share attributable to 3M common shareholders – basic | $ | | $ | | $ | | $ | | ||||
Earnings per share attributable to 3M common shareholders – diluted | $ | | $ | | $ | | $ | | ||||
New Accounting Pronouncements
Refer to Note 1 in 3M’s 2020 Annual Report on Form 10-K for a more detailed discussion of the standards in the tables that follow, except for those pronouncements issued subsequent to the most recent Form 10-K filing date for which separate, more detailed discussion is provided below as applicable.
Standards Adopted During the Current Fiscal Year | |||||
Standard | Relevant Description | Effective Date for 3M | Impact and Other Matters | ||
ASU No. 2019-12, Simplifying the Accounting for Income Taxes (Topic 740) | Eliminates certain existing exceptions related to the general approach in ASC 740 relating to franchise taxes, reducing complexity in the interim-period accounting for year-to-date loss limitations and changes in tax laws, and clarifying the accounting for transactions outside of business combination that result in a step-up in the tax basis of goodwill. | January 1, 2021 | Adoption of this ASU did not have a material impact on 3M’s consolidated results of operations and financial condition. | ||
ASU No. 2020-01, Clarifying the Interactions between Topic 321, Investments—Equity Securities, Topic 323, Investments—Equity Method and Joint Ventures, and Topic 815, Derivatives and Hedging | Clarifies when accounting for certain equity securities, a Company should consider observable transactions before applying or upon discontinuing the equity method of accounting for the purposes of applying the measurement alternative. Indicates when determining the accounting for certain derivatives, a Company should not consider if the underlying securities would be accounted for under the equity method or fair value option. | January 1, 2021 | Adoption of this ASU did not have a material impact on 3M’s consolidated results of operations and financial condition. | ||
ASU No. 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting and ASU No. 2021-01, Reference Rate Reform (Topic 848): Scope | Provides temporary optional expedients and exceptions to existing guidance on contract modifications and hedge accounting to facilitate the market transition from existing reference rates, such as LIBOR which is being phased out beginning at the end of 2021, to alternate reference rates, such as SOFR. | Effective upon ASUs’ issuances in 2020 & 2021 | With the beginning of the phase out of LIBOR at the end of 2021, 3M continues to evaluate commercial contracts that may utilize LIBOR and will continue to monitor developments during the LIBOR transition period. | ||
NOTE 2. Revenue
Contract Balances:
Deferred revenue primarily relates to revenue that is recognized over time for
9
2021, respectively, while approximately $
Operating Lease Revenue:
Net sales includes rental revenue from durable medical devices as part of operating lease arrangements (reported within the Medical Solutions Division), which was $
Disaggregated revenue information:
The Company views the following disaggregated disclosures as useful to understanding the composition of revenue recognized during the respective reporting periods:
Three months ended | Six months ended | ||||||||||||
June 30, | June 30, | ||||||||||||
Net Sales (Millions) | 2021 |
| 2020 |
| 2021 |
| 2020 | ||||||
Abrasives | $ | | $ | | $ | | $ | | |||||
Automotive Aftermarket | | | | | |||||||||
Closure and Masking Systems | | | | | |||||||||
Electrical Markets | | | | | |||||||||
Industrial Adhesives and Tapes | | | | | |||||||||
Personal Safety | | | | | |||||||||
Roofing Granules | | | | | |||||||||
Other Safety and Industrial | — | | — | | |||||||||
Total Safety and Industrial Business Segment | $ | | $ | | $ | | $ | | |||||
Advanced Materials | $ | | $ | | $ | | $ | | |||||
Automotive and Aerospace | | | | | |||||||||
Commercial Solutions | | | | | |||||||||
Electronics | | | | | |||||||||
Transportation Safety | | | | | |||||||||
Other Transportation and Electronics | ( | — | ( | ( | |||||||||
Total Transportation and Electronics Business Segment | $ | | $ | | | $ | | ||||||
Drug Delivery | $ | — | $ | | $ | — | $ | | |||||
Food Safety | | | | | |||||||||
Health Information Systems | | | | | |||||||||
Medical Solutions | | | | | |||||||||
Oral Care | | | | | |||||||||
Separation and Purification Sciences | | | | | |||||||||
Other Health Care | ( | | ( | — | |||||||||
Total Health Care Business Group | $ | | $ | | $ | | $ | | |||||
Consumer Health and Safety | $ | | $ | | $ | | $ | | |||||
Home Care | | | | | |||||||||
Home Improvement | | | | | |||||||||
Stationery and Office | | | | | |||||||||
Other Consumer | | | | | |||||||||
Total Consumer Business Group | $ | | $ | | $ | | $ | | |||||
Corporate and Unallocated | $ | | $ | | $ | ( | $ | | |||||
Elimination of Dual Credit | ( | ( | ( | ( | |||||||||
Total Company | $ | | $ | | $ | | $ | | |||||
10
Three months ended June 30, 2021 | ||||||||||||||||
Net Sales (Millions) |
| Americas | Asia Pacific |
| Europe, Middle East and Africa |
| Other Unallocated |
| Worldwide | |||||||
Safety and Industrial | $ | | $ | | $ | | $ | — | $ | | ||||||
Transportation and Electronics |
| |
| |
| |
| ( |
| | ||||||
Health Care | | | | ( | | |||||||||||
Consumer |
| |
| |
| |
| — |
| | ||||||
Corporate and Unallocated |
| |
| — |
| — |
| — |
| | ||||||
Elimination of Dual Credit |
| ( |
| ( |
| ( |
| |
| ( | ||||||
Total Company | $ | | $ | | $ | | $ | ( | $ | | ||||||
Six months ended June 30, 2021 | ||||||||||||||||
Net Sales (Millions) |
| Americas | Asia Pacific |
| Europe, Middle East and Africa |
| Other Unallocated |
| Worldwide | |||||||
Safety and Industrial | $ | | $ | | $ | | $ | — | $ | | ||||||
Transportation and Electronics |
| |
| |
| |
| ( |
| | ||||||
Health Care | | | | ( | | |||||||||||
Consumer |
| |
| |
| |
| — |
| | ||||||
Corporate and Unallocated |
| — |
| — |
| — |
| ( |
| ( | ||||||
Elimination of Dual Credit |
| ( |
| ( |
| ( |
| |
| ( | ||||||
Total Company | $ | | $ | | $ | | $ | ( | $ | | ||||||
Three months ended June 30, 2020 | ||||||||||||||||
Net Sales (Millions) |
| Americas | Asia Pacific |
| Europe, Middle East and Africa |
| Other Unallocated |
| Worldwide | |||||||
Safety and Industrial | $ | | $ | | $ | | $ | ( | $ | | ||||||
Transportation and Electronics |
| |
| |
| |
| — |
| | ||||||
Health Care | | | | ( | | |||||||||||
Consumer |
| |
| |
| |
| — |
| | ||||||
Corporate and Unallocated |
| ( |
| — |
| — |
| |
| | ||||||
Elimination of Dual Credit |
| ( |
| ( |
| ( |
| — |
| ( | ||||||
Total Company | $ | | $ | | $ | | $ | | $ | | ||||||
Six months ended June 30, 2020 | ||||||||||||||||
Net Sales (Millions) |
| Americas | Asia Pacific |
| Europe, Middle East and Africa |
| Other Unallocated |
| Worldwide | |||||||
Safety and Industrial | $ | | $ | | $ | | $ | ( | $ | | ||||||
Transportation and Electronics |
| |
| |
| |
| — |
| | ||||||
Health Care | | | | ( | | |||||||||||
Consumer |
| |
| |
| |
| ( |
| | ||||||
Corporate and Unallocated |
| ( |
| — |
| — |
| |
| | ||||||
Elimination of Dual Credit |
| ( |
| ( |
| ( |
| — |
| ( | ||||||
Total Company | $ | | $ | | $ | | $ | ( | $ | | ||||||
Americas included United States net sales to customers of $
11
NOTE 3. Acquisitions and Divestitures
Refer to Note 3 in 3M’s 2020 Annual Report on Form 10-K for more information on relevant pre-2021 acquisitions and divestitures.
Acquisitions:
3M makes acquisitions of certain businesses from time to time that are aligned with its strategic intent with respect to, among other factors, growth markets and adjacent product lines or technologies. Goodwill resulting from business combinations is largely attributable to the existing workforce of the acquired businesses and synergies expected to arise after 3M’s acquisition of these businesses.
2021 acquisitions:
There were
2020 acquisitions:
There were
Divestitures:
3M may divest certain businesses from time to time based upon review of the Company’s portfolio considering, among other items, factors relative to the extent of strategic and technological alignment and optimization of capital deployment, in addition to considering if selling the businesses results in the greatest value creation for the Company and for shareholders.
2021 divestitures:
There were
2020 divestitures:
During 2020, as described in Note 3 in 3M’s 2020 Annual Report on Form 10-K, the Company divested its advanced ballistic-protection business, substantially all of its drug delivery business, and a small dermatology products business.
Operating income and held for sale amounts:
The aggregate operating income of applicable businesses held for sale with respect to the first six months of 2020 was $
NOTE 4. Goodwill and Intangible Assets
There was
Goodwill
(Millions) | Safety and Industrial | Transportation and Electronics | Health Care | Consumer | Total Company | |||||||||||
Balance as of December 31, 2020 | $ | | $ | | $ | | $ | | $ | | ||||||
Translation and other | ( | ( | ( | ( | ( | |||||||||||
Balance as of June 30, 2021 | $ | | $ | | $ | | $ | | $ | | ||||||
12
Accounting standards require that goodwill be tested for impairment annually and between annual tests in certain circumstances such as a change in reporting units or the testing of recoverability of a significant asset group within a reporting unit. At 3M, reporting units correspond to a division.
As described in Note 16, effective in the first quarter of 2021, the Company changed its business segment reporting. For any product changes that resulted in reporting unit changes, the Company applied the relative fair value method to determine the impact on goodwill of the associated reporting units, the results of which were immaterial.
Acquired Intangible Assets
The carrying amount and accumulated amortization of acquired finite-lived intangible assets, in addition to the balance of non-amortizable intangible assets, as of June 30, 2021, and December 31, 2020, follow:
| June 30, |
| December 31, |
| |||
(Millions) |
| 2021 |
| 2020 |
| ||
Customer related intangible assets | $ | | $ | | |||
Patents |
| |
| | |||
Other technology-based intangible assets |
| |
| | |||
Definite-lived tradenames |
| |
| | |||
Other amortizable intangible assets |
| |
| | |||
Total gross carrying amount | $ | | $ | | |||
Accumulated amortization — customer related |
| ( |
| ( | |||
Accumulated amortization — patents |
| ( |
| ( | |||
Accumulated amortization — other technology-based |
| ( |
| ( | |||
Accumulated amortization — definite-lived tradenames |
| ( |
| ( | |||
Accumulated amortization — other |
| ( |
| ( | |||
Total accumulated amortization | $ | ( | $ | ( | |||
Total finite-lived intangible assets — net | $ | | $ | | |||
Non-amortizable intangible assets (primarily tradenames) |
| |
| | |||
Total intangible assets — net | $ | | $ | | |||
Certain tradenames acquired by 3M are not amortized because they have been in existence for over
Amortization expense for the three and six months ended June 30, 2021 and 2020 follows:
| Three months ended |
| Six months ended |
| |||||||||
June 30, | June 30, | ||||||||||||
(Millions) |
| 2021 |
| 2020 |
| 2021 | 2020 |
| |||||
Amortization expense | $ | | $ | | $ | | $ | | |||||
Expected amortization expense for acquired amortizable intangible assets recorded as of June 30, 2021:
Remainder of | After |
| ||||||||||||||||||||
(Millions) | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2026 |
| ||||||||||||||
Amortization expense | $ | | $ | | $ | | $ | | $ | | $ | | $ | | ||||||||
The preceding expected amortization expense is an estimate. Actual amounts of amortization expense may differ from estimated amounts due to additional intangible asset acquisitions, changes in foreign currency exchange rates, impairment of intangible assets,
13
accelerated amortization of intangible assets and other events. 3M expenses the costs incurred to renew or extend the term of intangible assets.
NOTE 5. Restructuring Actions
2020 and 2021 Restructuring Actions:
Operational/Marketing Capability Restructuring:
As described in Note 5 in 3M’s 2020 Annual Report on Form 10-K, in late 2020, 3M announced it would undertake certain actions to further enhance its operations and marketing capabilities to take advantage of certain global market trends while de-prioritizing investments in slower-growth end markets. During the fourth quarter of 2020, management approved and committed to undertake associated restructuring actions impacting approximately
(Millions) | First Six Months of 2021 | ||
Cost of sales | $ | | |
Selling, general and administrative expenses |
| | |
Research, development and related expenses |
| | |
Total operating income impact | $ | | |
The business segment operating income impact of these restructuring charges is summarized as follows:
First Six Months of 2021 | |||
(Millions) |
| Employee-Related | |
Safety and Industrial | $ | | |
Transportation and Electronics | | ||
Health Care | | ||
Consumer | | ||
Corporate and Unallocated |
| | |
Total Operating Expense | $ | | |
14
Restructuring actions, including cash and non-cash impacts, follow:
(Millions) |
| Employee-Related |
| |
Accrued restructuring action balances as of December 31, 2020 | $ | | ||
Incremental expense incurred in the first quarter of 2021 | | |||
Incremental expense incurred in the second quarter of 2021 | | |||
Cash payments |
| ( | ||
Adjustments | ( | |||
Accrued restructuring action balances as of June 30, 2021 | $ | | ||
Divestiture-Related Restructuring
As described in Note 5 in 3M’s 2020 Annual Report on Form 10-K, during the second quarter of 2020, following the divestiture of substantially all of the drug delivery business, management approved and committed to undertake certain restructuring actions addressing corporate functional costs and manufacturing footprint across 3M in relation to the magnitude of amounts previously allocated/burdened to the divested business. These actions affected approximately
Divestiture-related restructuring actions, including cash and non-cash impacts, follow:
(Millions) |
| Employee-Related |
| Asset-Related and Other |
| Total |
| |||
Accrued divestiture-related restructuring action balances as of December 31, 2020 | $ | | $ | | $ | | ||||
Cash payments | ( | — | ( | |||||||
Adjustments | ( | — | ( | |||||||
Accrued divestiture-related restructuring action balances as of June 30, 2021 | $ | | $ | | $ | | ||||
Remaining activities related to this divestiture-related restructuring are expected to be largely completed through the third quarter of 2021.
Other Restructuring
As described in Note 5 in 3M’s 2020 Annual Report on Form 10-K, in the second quarter of 2020, management approved and committed to undertake certain restructuring actions addressing structural enterprise costs and operations in certain end markets as a result of the COVID-19 pandemic and related economic impacts. These actions affected approximately
Restructuring actions, including cash and non-cash impacts, follow:
(Millions) |
| Employee-Related |
| |
Accrued restructuring action balances as of December 31, 2020 | $ | | ||
Cash payments | ( | |||
Adjustments | ( | |||
Accrued restructuring action balances as of March 31, 2021 | $ | | ||
Remaining activities related to this restructuring were largely completed in the second quarter of 2021.
15
NOTE 6. Supplemental Income Statement Information
Other expense (income), net consists of the following:
| Three months ended |
| Six months ended | ||||||||||
June 30, | June 30, | ||||||||||||
(Millions) | 2021 |
| 2020 |
| 2021 | 2020 | |||||||
Interest expense | $ | | $ | | $ | | $ | | |||||
Interest income |
| ( |
| ( |
| ( |
| ( | |||||
Pension and postretirement net periodic benefit cost (benefit) | ( | ( | ( | ( | |||||||||
Total | $ | | $ | | $ | | $ | | |||||
Interest expense includes an early debt extinguishment pre-tax charge of approximately $
Pension and postretirement net periodic benefit costs described in the table above include all components of defined benefit plan net periodic benefit costs except service cost, which is reported in various operating expense lines. Refer to Note 11 for additional details on the components of pension and postretirement net periodic benefit costs.
NOTE 7. Supplemental Equity and Comprehensive Income Information
Cash dividends declared and paid totaled $
Consolidated Changes in Equity
Three months ended June 30, 2021
3M Company Shareholders |
| ||||||||||||||||||
Common | Accumulated |
| |||||||||||||||||
Stock and | Other |
| |||||||||||||||||
Additional | Comprehensive | Non- |
| ||||||||||||||||
Paid-in | Retained | Treasury | Income | controlling |
| ||||||||||||||
(Millions) |
| Total |
| Capital |
| Earnings |
| Stock |
| (Loss) |
| Interest |
| ||||||
Balance at March 31, 2021 |
| $ | |
| $ | |
| $ | |
| $ | ( |
| $ | ( |
| $ | | |
Net income |
| |
| |
| | |||||||||||||
Other comprehensive income (loss), net of tax: | |||||||||||||||||||
Cumulative translation adjustment |
| |
| |
| ( | |||||||||||||
Defined benefit pension and post-retirement plans adjustment |
| |
| |
| — | |||||||||||||
Cash flow hedging instruments |
| ( |
| ( |
| — | |||||||||||||
Total other comprehensive income (loss), net of tax |
| | |||||||||||||||||
Dividends declared |
| ( |
| ( | |||||||||||||||
Stock-based compensation |
| |
| | |||||||||||||||
Reacquired stock |
| ( |
| ( | |||||||||||||||
Issuances pursuant to stock option and benefit plans |
| |
| ( |
| | |||||||||||||
Balance at June 30, 2021 |
| $ | |
| $ | |
| $ | |
| $ | ( |
| $ | ( |
| $ | | |
16
Six months ended June 30, 2021
3M Company Shareholders |
| ||||||||||||||||||
Common | Accumulated |
| |||||||||||||||||
Stock and | Other |
| |||||||||||||||||
Additional | Comprehensive | Non- |
| ||||||||||||||||
Paid-in | Retained | Treasury | Income | controlling |
| ||||||||||||||
(Millions) |
| Total |
| Capital |
| Earnings |
| Stock |
| (Loss) |
| Interest |
| ||||||
Balance at December 31, 2020 |
| $ | |
| $ | |
| $ | |
| $ | ( |
| $ | ( |
| $ | | |
Net income |
| |
| |
| | |||||||||||||
Other comprehensive income (loss), net of tax: | |||||||||||||||||||
Cumulative translation adjustment |
| ( |
| ( |
| — | |||||||||||||
Defined benefit pension and post-retirement plans adjustment |
| |
| |
| — | |||||||||||||
Cash flow hedging instruments |
| |
| |
| — | |||||||||||||
Total other comprehensive income (loss), net of tax |
| | |||||||||||||||||
Dividends declared |
| ( |
| ( | |||||||||||||||
Stock-based compensation |
| |
| | |||||||||||||||
Reacquired stock |
| ( |
| ( | |||||||||||||||
Issuances pursuant to stock option and benefit plans |
| |
| ( |
| | |||||||||||||
Balance at June 30, 2021 |
| $ | |
| $ | |
| $ | |
| $ | ( |
| $ | ( |
| $ | | |
Three months ended June 30, 2020
3M Company Shareholders |
| ||||||||||||||||||
Common | Accumulated |
| |||||||||||||||||
Stock and | Other |
| |||||||||||||||||
Additional | Comprehensive | Non- |
| ||||||||||||||||
Paid-in | Retained | Treasury | Income | controlling |
| ||||||||||||||
(Millions) |
| Total |
| Capital |
| Earnings |
| Stock |
| (Loss) |
| Interest |
| ||||||
Balance at March 31, 2020 |
| $ | |
| $ | |
| $ | |
| $ | ( |
| $ | ( |
| $ | | |
Net income |
| |
| |
| ( | |||||||||||||
Other comprehensive income (loss), net of tax: | |||||||||||||||||||
Cumulative translation adjustment |
| |
| |
| — | |||||||||||||
Defined benefit pension and post-retirement plans adjustment |
| |
| |
| — | |||||||||||||
Cash flow hedging instruments |
| ( |
| ( |
| — | |||||||||||||
Total other comprehensive income (loss), net of tax |
| | |||||||||||||||||
Dividends declared |
| ( |
| ( | |||||||||||||||
Purchase of subsidiary shares | ( | ( | |||||||||||||||||
Stock-based compensation |
| |
| | |||||||||||||||
Reacquired stock |
| — |
| — | |||||||||||||||
Issuances pursuant to stock option and benefit plans |
| |
| ( |
| | |||||||||||||
Balance at June 30, 2020 |
| $ | |
| $ | |
| $ | |
| $ | ( |
| $ | ( |
| $ | | |
17
Six months ended June 30, 2020
3M Company Shareholders |
| ||||||||||||||||||
Common | Accumulated |
| |||||||||||||||||
Stock and | Other |
| |||||||||||||||||
Additional | Comprehensive | Non- |
| ||||||||||||||||
Paid-in | Retained | Treasury | Income | controlling |
| ||||||||||||||
(Millions) |
| Total |
| Capital |
| Earnings |
| Stock |
| (Loss) |
| Interest |
| ||||||
Balance at December 31, 2019 |
| $ | |
| $ | |
| $ | |
| $ | ( |
| $ | ( |
| $ | | |
Net income |
| |
| |
| ( | |||||||||||||
Other comprehensive income (loss), net of tax: | |||||||||||||||||||
Cumulative translation adjustment |
| ( |
| ( |
| ( | |||||||||||||
Defined benefit pension and post-retirement plans adjustment |
| |
| |
| — | |||||||||||||
Cash flow hedging instruments |
| |
| |
| — | |||||||||||||
Total other comprehensive income (loss), net of tax |
| ( | |||||||||||||||||
Dividends declared |
| ( |
| ( | |||||||||||||||
Purchase of subsidiary shares | ( | ( | |||||||||||||||||
Stock-based compensation |
| |
| | |||||||||||||||
Reacquired stock |
| ( |
| ( | |||||||||||||||
Issuances pursuant to stock option and benefit plans |
| |
| ( |
| | |||||||||||||
Balance at June 30, 2020 |
| $ | |
| $ | |
| $ | |
| $ | ( |
| $ | ( |
| $ | | |
Changes in Accumulated Other Comprehensive Income (Loss) Attributable to 3M by Component
Three months ended June 30, 2021 |
|
|
|
|
| ||||||||
Defined Benefit | Cash Flow | Total |
| ||||||||||
Pension and | Hedging | Accumulated |
| ||||||||||
Cumulative | Postretirement | Instruments, | Other |
| |||||||||
Translation | Plans | Unrealized | Comprehensive |
| |||||||||
(Millions) | Adjustment | Adjustment | Gain (Loss) | Income (Loss) |
| ||||||||
Balance at March 31, 2021, net of tax: | $ | ( | $ | ( | $ | ( | $ | ( | |||||
Other comprehensive income (loss), before tax: | |||||||||||||
Amounts before reclassifications |
| |
| — |
| ( |
| | |||||
Amounts reclassified out |
| — |
| |
| |
| | |||||
Total other comprehensive income (loss), before tax |
| |
| |
| ( |
| | |||||
Tax effect |
| |
| ( |
| |
| ( | |||||
Total other comprehensive income (loss), net of tax |
| |
| |
| ( |
| | |||||
Balance at June 30, 2021, net of tax: | $ | ( | $ | ( | $ | ( | $ | ( | |||||
Six months ended June 30, 2021 |
|
|
|
|
| ||||||||
Defined Benefit | Cash Flow | Total |
| ||||||||||
Pension and | Hedging | Accumulated |
| ||||||||||
Cumulative | Postretirement | Instruments, | Other |
| |||||||||
Translation | Plans | Unrealized | Comprehensive |
| |||||||||
(Millions) | Adjustment | Adjustment | Gain (Loss) | Income (Loss) |
| ||||||||
Balance at December 31, 2020, net of tax: | $ | ( | $ | ( | $ | ( | $ | ( | |||||
Other comprehensive income (loss), before tax: | |||||||||||||
Amounts before reclassifications |
| ( |
| — |
| |
| | |||||
Amounts reclassified out |
| — |
| |
| |
| | |||||
Total other comprehensive income (loss), before tax |
| ( |
| |
| |
| | |||||
Tax effect |
| ( |
| ( |
| ( |
| ( | |||||
Total other comprehensive income (loss), net of tax |
| ( |
| |
| |
| | |||||
Balance at June 30, 2021, net of tax: | $ | ( | $ | ( | $ | ( | $ | ( | |||||
18
Three months ended June 30, 2020 |
|
|
|
|
| ||||||||
Defined Benefit | Cash Flow | Total |
| ||||||||||
Pension and | Hedging | Accumulated |
| ||||||||||
Cumulative | Postretirement | Instruments, | Other |
| |||||||||
Translation | Plans | Unrealized | Comprehensive |
| |||||||||
(Millions) | Adjustment | Adjustment | Gain (Loss) | Income (Loss) |
| ||||||||
Balance at March 31, 2020, net of tax: | $ | ( | $ | ( | $ | | $ | ( | |||||
Other comprehensive income (loss), before tax: | |||||||||||||
Amounts before reclassifications |
| |
| ( |
| ( |
| | |||||
Amounts reclassified out |
| — |
| |
| ( |
| | |||||
Total other comprehensive income (loss), before tax |
| |
| |
| ( |
| | |||||
Tax effect |
| |
| ( |
| |
| ( | |||||
Total other comprehensive income (loss), net of tax |
| |
| |
| ( |
| | |||||
Balance at June 30, 2020, net of tax: | $ | ( | $ | ( | $ | ( | $ | ( | |||||
Six months ended June 30, 2020 |
|
|
|
|
| ||||||||
Defined Benefit | Cash Flow | Total |
| ||||||||||
Pension and | Hedging | Accumulated |
| ||||||||||
Cumulative | Postretirement | Instruments, | Other |
| |||||||||
Translation | Plans | Unrealized | Comprehensive |
| |||||||||
(Millions) | Adjustment | Adjustment | Gain (Loss) | Income (Loss) |
| ||||||||
Balance at December 31, 2019, net of tax: | $ | ( | $ | ( | $ | ( | $ | ( | |||||
Other comprehensive income (loss), before tax: | |||||||||||||
Amounts before reclassifications |
| ( |
| ( |
| |
| ( | |||||
Amounts reclassified out |
| — |
| |
| ( |
| | |||||
Total other comprehensive income (loss), before tax |
| ( |
| |
| |
| ( | |||||
Tax effect |
| — |
| ( |
| ( |
| ( | |||||
Total other comprehensive income (loss), net of tax |
| ( |
| |
| |
| ( | |||||
Balance at June 30, 2020, net of tax | $ | ( | $ | ( | $ | ( | $ | ( | |||||
Income taxes are not provided for foreign translation relating to permanent investments in international subsidiaries, but tax effects within cumulative translation does include impacts from items such as net investment hedge transactions. Reclassification adjustments are made to avoid double counting in comprehensive income items that are subsequently recorded as part of net income.
Reclassifications out of Accumulated Other Comprehensive Income Attributable to 3M
Amount Reclassified from |
| ||||||||||||||
Details about Accumulated Other | Accumulated Other Comprehensive Income | ||||||||||||||
Comprehensive Income Components | Three months ended June 30, | Six months ended June 30, | Location on Income |
| |||||||||||
(Millions) | 2021 |
| 2020 |
| 2021 |
| 2020 | Statement |
| ||||||
Defined benefit pension and postretirement plans adjustments | |||||||||||||||
Gains (losses) associated with defined benefit pension and postretirement plans amortization | |||||||||||||||
Transition asset | $ | ( | $ | — | $ | ( |
| $ | ( |
| See Note 11 | ||||
Prior service benefit | | | |
| |
| See Note 11 | ||||||||
Net actuarial loss | ( | ( | ( | ( | See Note 11 | ||||||||||
Curtailments/Settlements |
| ( |
| ( |
| ( |
|
| ( |
| See Note 11 | ||||
Total before tax |
| ( |
| ( |
| ( |
| ( | |||||||
Tax effect |
| |
| |
| |
|
| |
| Provision for income taxes | ||||
Net of tax | $ | ( | $ | ( | $ | ( | $ | ( | |||||||
Cash flow hedging instruments gains (losses) | |||||||||||||||
Foreign currency forward/option contracts | $ | ( | $ | | $ | ( |
| $ | |
| Cost of sales | ||||
Interest rate contracts |
| ( |
| ( |
| ( |
|
| ( |
| Interest expense | ||||
Total before tax |
| ( |
| |
| ( |
| | |||||||
Tax effect |
| |
| ( |
| |
|
| ( |
| Provision for income taxes | ||||
Net of tax | $ | ( | $ | | $ | ( | $ | | |||||||
Total reclassifications for the period, net of tax | $ | ( | $ | ( | $ | ( | $ | ( | |||||||
19
NOTE 8. Income Taxes
The IRS has completed its field examination of the Company’s U.S. federal income tax returns through 2018, but the years 2005 through 2017 have not closed as the Company is in the process of resolving issues identified during those examinations. In addition to the U.S. federal examination, there is also audit activity in several U.S. state and foreign jurisdictions where the Company is subject to ongoing tax examinations and governmental assessments, which could be impacted by evolving political environments in those jurisdictions. As of June 30, 2021, no taxing authority proposed significant adjustments to the Company’s tax positions for which the Company is not adequately reserved.
It is reasonably possible that the amount of unrecognized tax benefits could significantly change within the next 12 months. At this time, the Company is not able to estimate the range by which these potential events could impact 3M’s unrecognized tax benefits in the next 12 months. The total amounts of unrecognized tax benefits that, if recognized, would affect the effective tax rate as of June 30, 2021 and December 31, 2020 are $
As of June 30, 2021 and December 31, 2020, the Company had valuation allowances of $
The effective tax rate for the second quarter and first six months of 2021 was
NOTE 9. Marketable Securities
The Company invests in asset-backed securities, certificates of deposit/time deposits, commercial paper, and other securities. The following is a summary of amounts recorded on the Consolidated Balance Sheet for marketable securities (current and non-current).
(Millions) | June 30, 2021 | December 31, 2020 |
| ||||
Corporate debt securities | $ | | $ | | |||
Commercial paper | | | |||||
Certificates of deposit/time deposits |
| |
| | |||
U.S. treasury securities | | | |||||
U.S. municipal securities |
| |
| | |||
Current marketable securities | $ | | $ | | |||
U.S. municipal securities | $ | | $ | | |||
Non-current marketable securities | $ | | $ | | |||
Total marketable securities | $ | | $ | | |||
At June 30, 2021 and December 31, 2020, gross unrealized, gross realized, and net realized gains and/or losses (pre-tax) were not material.
The balances at June 30, 2021 for marketable securities by contractual maturity are shown below. Actual maturities may differ from contractual maturities because the issuers of the securities may have the right to prepay obligations without prepayment penalties.
(Millions) |
| June 30, 2021 |
| |
Due in one year or less | $ | | ||
Due after one year through five years |
| | ||
Due after five years through ten years |
| | ||
Total marketable securities | $ | | ||
20
NOTE 10. Long-Term Debt and Short-Term Borrowings
In March 2021, 3M, via a make-whole call offer, redeemed $
In the second quarter of 2021, 3M entered into interest rate swaps with a notional amount of $
2020 issuances, maturities, and extinguishments of short- and long-term debt are described in Note 5 in 3M’s 2020 Annual Report on Form 10-K.
The Company had
Future Maturities of Long-term Debt
Maturities of long-term debt in the table below reflect the impact of put provisions associated with certain debt instruments and are net of the unaccreted debt issue costs such that total maturities equal the carrying value of long-term debt as of June 30, 2021. The maturities of long-term debt for the periods subsequent to June 30, 2021 are as follows (in millions):
Remainder of |
|
|
|
|
|
| After |
|
| ||||||||||||||
2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2026 | Total |
| |||||||||||||||
$ | | $ | | $ | | $ | | $ | | $ | | $ | | $ | | ||||||||
NOTE 11. Pension and Postretirement Benefit Plans
As discussed in Note 1, effective in the first quarter of 2021, 3M made a change in accounting principle for net periodic pension and postretirement plan cost. This impacted the expected return on plan assets and the amortization of net unamortized actuarial gains or losses expense components of net periodic benefit cost. This change was applied retrospectively to all periods presented within 3M’s financial statements.
The service cost component of defined benefit net periodic benefit cost is recorded in cost of sales; selling, general and administrative expenses; and research, development and related expenses. The other components of net periodic benefit cost are reflected in other
21
expense (income), net. Components of net periodic benefit cost and other supplemental information for the three and six months ended June 30, 2021 and 2020 follow:
Benefit Plan Information
Three months ended June 30, | ||||||||||||||||||
Qualified and Non-qualified | ||||||||||||||||||
Pension Benefits | Postretirement | |||||||||||||||||
United States | International | Benefits | ||||||||||||||||
(Millions) |
| 2021 |
| 2020 |
| 2021 |
| 2020 |
| 2021 |
| 2020 | ||||||
Net periodic benefit cost (benefit) | ||||||||||||||||||
Operating expense | ||||||||||||||||||
Service cost | $ | | $ | | $ | | $ | | $ | | $ | | ||||||
Non-operating expense | ||||||||||||||||||
Interest cost | $ | | $ | | $ | | $ | | $ | | $ | | ||||||
Expected return on plan assets |
| ( |
| ( |
| ( |
| ( |
| ( |
| ( | ||||||
Amortization of transition asset |
| — |
| — |
| |
| — |
| — |
| — | ||||||
Amortization of prior service benefit |
| ( |
| ( |
| ( |
| ( |
| ( |
| ( | ||||||
Amortization of net actuarial loss | | | | | | | ||||||||||||
Settlements, curtailments, special termination benefits and other |
| — |
| — |
| — |
| — |
| |
| | ||||||
Total non-operating expense (benefit) | ( | ( | ( | ( | ( | — | ||||||||||||
Total net periodic benefit cost (benefit) | $ | | $ | | $ | | $ | | $ | | $ | | ||||||
Six months ended June 30, | ||||||||||||||||||
Qualified and Non-qualified | ||||||||||||||||||
Pension Benefits | Postretirement | |||||||||||||||||
United States | International | Benefits | ||||||||||||||||
(Millions) |
| 2021 |
| 2020 |
| 2021 |
| 2020 |
| 2021 |
| 2020 | ||||||
Net periodic benefit cost (benefit) | ||||||||||||||||||
Operating expense | ||||||||||||||||||
Service cost | $ | | $ | | $ | | $ | | $ | | $ | | ||||||
Non-operating expense | ||||||||||||||||||
Interest cost | $ | | $ | | $ | | $ | | $ | | $ | | ||||||
Expected return on plan assets |
| ( |
| ( |
| ( |
| ( |
| ( |
| ( | ||||||
Amortization of transition asset |
| — |
| — |
| |
| |
| — |
| — | ||||||
Amortization of prior service benefit |
| ( |
| ( |
| ( |
| ( |
| ( |
| ( | ||||||
Amortization of net actuarial loss | | | | | | | ||||||||||||
Settlements, curtailments, special termination benefits and other |
| — |
| — |
| — |
| — |
| |
| | ||||||
Total non-operating expense (benefit) | ( | ( | ( | ( | ( | | ||||||||||||
Total net periodic benefit cost (benefit) | $ | | $ | | $ | | $ | | $ | | $ | | ||||||
For the six months ended June 30, 2021 contributions totaling $
NOTE 12. Derivatives
The Company uses interest rate swaps, currency swaps, and forward and option contracts to manage risks generally associated with foreign exchange rate, interest rate and commodity price fluctuations. The information that follows explains the various types of derivatives and financial instruments used by 3M, how and why 3M uses such instruments, how such instruments are accounted for, and how such instruments impact 3M’s financial position and performance.
Additional information with respect to derivatives is included elsewhere as follows:
| ● | Impact on other comprehensive income of nonderivative hedging and derivative instruments is included in Note 7. |
| ● | Fair value of derivative instruments is included in Note 13. |
| ● | Derivatives and/or hedging instruments associated with the Company’s long-term debt are described in Note 12 in 3M’s 2020 Annual Report on Form 10-K. |
22
Types of Derivatives/Hedging Instruments and Inclusion in Income/Other Comprehensive Income
Cash Flow Hedges:
For derivative instruments that are designated and qualify as cash flow hedges, the gain or loss on the derivative is reported as a component of other comprehensive income and reclassified into earnings in the same period during which the hedged transaction affects earnings. Gains and losses on the derivative representing hedge components excluded from the assessment of effectiveness are recognized in current earnings.
Cash Flow Hedging - Foreign Currency Forward and Option Contracts: The Company enters into foreign exchange forward and option contracts to hedge against the effect of exchange rate fluctuations on cash flows denominated in foreign currencies. These transactions are designated as cash flow hedges. The settlement or extension of these derivatives will result in reclassifications (from accumulated other comprehensive income) to earnings in the period during which the hedged transactions affect earnings. 3M may dedesignate these cash flow hedge relationships in advance of the occurrence of the forecasted transaction. The portion of gains or losses on the derivative instrument previously included in accumulated other comprehensive income for dedesignated hedges remains in accumulated other comprehensive income until the forecasted transaction occurs or becomes probable of not occurring. Changes in the value of derivative instruments after dedesignation are recorded in earnings and are included in the Derivatives Not Designated as Hedging Instruments section below. The maximum length of time over which 3M hedges its exposure to the variability in future cash flows of the forecasted transactions is
Cash Flow Hedging - Interest Rate Contracts: The Company may use forward starting interest rate contracts and treasury rate lock contracts to hedge exposure to variability in cash flows from interest payments on forecasted debt issuances. The amortization of gains and losses on forward starting interest rate swaps is included in the tables below as part of the gain/(loss) reclassified from accumulated other comprehensive income into income. Additional information regarding previously issued but terminated interest rate contracts, which have related balances within accumulated other comprehensive income being amortized over the underlying life of related debt, can be found in Note 14 in 3M’s 2020 Annual Report on Form 10-K.
As of June 30, 2021, the Company had a balance of $
The location in the consolidated statements of income and comprehensive income and amounts of gains and losses related to derivative instruments designated as cash flow hedges are provided in the following table. Reclassifications of amounts from accumulated other comprehensive income into income include accumulated gains (losses) on dedesignated hedges at the time earnings are impacted by the forecasted transactions.
Pretax Gain (Loss) Recognized in Other | Pretax Gain (Loss) Reclassified from Accumulated | |||||||||||||
Comprehensive Income on Derivative | Other Comprehensive Income into Income | |||||||||||||
Three months ended June 30, | Three months ended June 30, | |||||||||||||
2021 | 2020 | 2021 | 2020 | |||||||||||
(Millions) |
| Amount | Amount | Location |
| Amount | Amount | |||||||
Foreign currency forward/option contracts | $ | ( | $ | ( | Cost of sales | $ | ( | $ | | |||||
Interest rate contracts |
| — |
| — | Interest expense |
| ( |
| ( | |||||
Total | $ | ( | $ | ( | $ | ( | $ | | ||||||
Six months ended June 30, | Six months ended June 30, | |||||||||||||
2021 | 2020 | 2021 | 2020 | |||||||||||
(Millions) |
| Amount | Amount | Location |
| Amount | Amount | |||||||
Foreign currency forward/option contracts | $ | | $ | | Cost of sales | $ | ( | $ | | |||||
Interest rate contracts |
| — |
| ( | Interest expense |
| ( |
| ( | |||||
Total | $ | | $ | | $ | ( | $ | | ||||||
23
Fair Value Hedges:
For derivative instruments that are designated and qualify as fair value hedges, the gain or loss on the derivatives as well as the offsetting loss or gain on the hedged item attributable to the hedged risk are recognized in current earnings.
Fair Value Hedging - Interest Rate Swaps: The Company manages interest expense using a mix of fixed and floating rate debt. To help manage borrowing costs, the Company may enter into interest rate swaps. Under these arrangements, the Company agrees to exchange, at specified intervals, the difference between fixed and floating interest amounts calculated by reference to an agreed-upon notional principal amount. The mark-to-market of these fair value hedges is recorded as gains or losses in interest expense and is offset by the gain or loss of the underlying debt instrument, which also is recorded in interest expense. Additional information regarding designated interest rate swaps can be found in Note 14 in 3M’s 2020 Annual Report on Form 10-K.
In the second quarter of 2021, 3M entered into interest rate swaps with a notional amount of $
Refer to the section below titled Statement of Income Location and Impact of Cash Flow and Fair Value Derivative Instruments for details on the location within the consolidated statements of income for amounts of gains and losses related to derivative instruments designated as fair value hedges and similar information relative to the hedged items for the three and six months ended June 30, 2021 and 2020.
The following amounts were recorded on the consolidated balance sheet related to cumulative basis adjustments for fair value hedges:
Cumulative Amount of Fair Value Hedging | ||||||||||||
Carrying Value of the | Adjustment Included in the Carrying Value | |||||||||||
(Millions) | Hedged Liabilities | of the Hedged Liabilities | ||||||||||
Location on the Consolidated Balance Sheet |
| June 30, 2021 |
| December 31, 2020 |
| June 30, 2021 |
| December 31, 2020 | ||||
Short-term borrowings and current portion of long-term debt |
| $ | | $ | |
| $ | | $ | | ||
Long-term debt | | | | | ||||||||
Total | $ | | $ | | $ | | $ | | ||||
Net Investment Hedges:
The Company may use non-derivative (foreign currency denominated debt) and derivative (foreign exchange forward contracts) instruments to hedge portions of the Company’s investment in foreign subsidiaries and manage foreign exchange risk. For instruments that are designated and qualify as hedges of net investments in foreign operations and that meet the effectiveness requirements, the net gains or losses attributable to changes in spot exchange rates are recorded in cumulative translation within other comprehensive income. The remainder of the change in value of such instruments is recorded in earnings. Recognition in earnings of amounts previously recorded in cumulative translation is limited to circumstances such as complete or substantially complete liquidation of the net investment in the hedged foreign operation. To the extent foreign currency denominated debt is not designated in or is dedesignated from a net investment hedge relationship, changes in value of that portion of foreign currency denominated debt due to exchange rate changes are recorded in earnings through their maturity date.
3M’s use of foreign exchange forward contracts designated in hedges of the Company’s net investment in foreign subsidiaries can vary by time period depending on when foreign currency denominated debt balances designated in such relationships are dedesignated, matured, or are newly issued and designated. Additionally, variation can occur in connection with the extent of the Company’s desired foreign exchange risk coverage.
At June 30, 2021, the total notional amount of foreign exchange forward contracts designated in net investment hedges was approximately
24
The location in the consolidated statements of income and comprehensive income and amounts of gains and losses related to derivative and nonderivative instruments designated as net investment hedges are as follows. There were no reclassifications of the effective portion of net investment hedges out of accumulated other comprehensive income into income for the periods presented in the table below.
Pretax Gain (Loss) Recognized | Amount of Gain (Loss) Excluded | |||||||||||||
as Cumulative Translation within | from Effectiveness Testing | |||||||||||||
Other Comprehensive Income | Recognized in Income | |||||||||||||
Three months ended June 30, | Three months ended June 30, | |||||||||||||
2021 | 2020 | 2021 | 2020 | |||||||||||
(Millions) |
| Amount | Amount | Location | Amount | Amount | ||||||||
Foreign currency denominated debt | $ | ( | $ | ( | Cost of sales | $ | — | $ | — | |||||
Foreign currency forward contracts |
| ( |
| | Cost of sales |
| |
| — | |||||
Total | $ | ( | $ | ( | $ | | $ | — | ||||||
Six months ended June 30, | Six months ended June 30, | |||||||||||||
2021 | 2020 | 2021 | 2020 | |||||||||||
Six months ended June 30, 2021 (Millions) |
| Amount | Amount | Location | Amount | Amount | ||||||||
Foreign currency denominated debt | $ | | $ | | Cost of sales | $ | — | $ | — | |||||
Foreign currency forward contracts |
| |
| | Cost of sales |
| — |
| | |||||
Total | $ | | $ | | $ | — | $ | | ||||||
Derivatives Not Designated as Hedging Instruments:
Derivatives not designated as hedging instruments include dedesignated foreign currency forward and option contracts that formerly were designated in cash flow hedging relationships (as referenced in the Cash Flow Hedges section above). In addition, 3M enters into foreign currency contracts that are not designated in hedging relationships to offset, in part, the impacts of changes in value of various non-functional currency denominated items including certain intercompany financing balances. These derivative instruments are not designated in hedging relationships; therefore, fair value gains and losses on these contracts are recorded in earnings. The Company does not hold or issue derivative financial instruments for trading purposes.
The location in the consolidated statement of income and amounts of gains and losses related to derivative instruments not designated as hedging instruments are as follows:
Gain (Loss) on Derivative Recognized in Income | ||||||||||||||
Three months ended June 30, | Six months ended June 30, | |||||||||||||
2021 | 2020 | 2021 | 2020 | |||||||||||
(Millions) |
| Location |
| Amount | Amount | Amount | Amount | |||||||
Foreign currency forward/option contracts |
| Cost of sales | $ | — | $ | ( | $ | — | $ | | ||||
Foreign currency forward contracts |
| Interest expense |
| |
| ( |
| |
| ( | ||||
Total | $ | | $ | ( | $ | | $ | ( | ||||||
25
Statement of Income Location and Impact of Cash Flow and Fair Value Derivative Instruments
The location in the consolidated statement of income and pre-tax amounts recognized in income related to derivative instruments designated in a cash flow or fair value hedging relationship are as follows:
Location and Amount of Gain (Loss) Recognized in Income | Location and Amount of Gain (Loss) Recognized in Income | ||||||||||||
Three months ended June 30, 2021 | Six months ended June 30, 2021 | ||||||||||||
(Millions) | Cost of sales | Other expense | Cost of sales | Other expense | |||||||||
Total amounts of income and expense line items presented in the consolidated statement of income in which the effects of cash flow or fair value hedges are recorded | $ | | $ | | $ | | $ | | |||||
The effects of cash flow and fair value hedging: | |||||||||||||
Gain or (loss) on cash flow hedging relationships: | |||||||||||||
Foreign currency forward/option contracts: | |||||||||||||
Amount of gain or (loss) reclassified from accumulated other comprehensive income into income | $ | ( | $ | — | $ | ( | $ | — | |||||
Interest rate contracts: | |||||||||||||
Amount of gain or (loss) reclassified from accumulated other comprehensive income into income | — | ( | — | ( | |||||||||
Gain or (loss) on fair value hedging relationships: | |||||||||||||
Interest rate contracts: | |||||||||||||
Hedged items | $ | — | $ | ( | $ | — | $ | — | |||||
Derivatives designated as hedging instruments | — | | — | — | |||||||||
Location and Amount of Gain (Loss) Recognized in Income | Location and Amount of Gain (Loss) Recognized in Income | ||||||||||||
Three months ended June 30, 2020 | Six months ended June 30, 2020 | ||||||||||||
(Millions) | Cost of sales | Other expense | Cost of sales | Other expense | |||||||||
Total amounts of income and expense line items presented in the consolidated statement of income in which the effects of cash flow or fair value hedges are recorded | $ | | $ | | $ | | $ | | |||||
The effects of cash flow and fair value hedging: | |||||||||||||
Gain or (loss) on cash flow hedging relationships: | |||||||||||||
Foreign currency forward/option contracts: | |||||||||||||
Amount of gain or (loss) reclassified from accumulated other comprehensive income into income | $ | | $ | — | $ | | $ | — | |||||
Interest rate contracts: | |||||||||||||
Amount of gain or (loss) reclassified from accumulated other comprehensive income into income | — | ( | — | ( | |||||||||
Gain or (loss) on fair value hedging relationships: | |||||||||||||
Interest rate contracts: | |||||||||||||
Hedged items | $ | — | $ | | $ | — | $ | — | |||||
Derivatives designated as hedging instruments | — | ( | — | — | |||||||||
Location and Fair Value Amount of Derivative Instruments
The following tables summarize the fair value of 3M’s derivative instruments, excluding nonderivative instruments used as hedging instruments, and their location in the consolidated balance sheet. Notional amounts below are presented at period end foreign
26
exchange rates, except for certain interest rate swaps, which are presented using the inception date’s foreign exchange rate. Additional information with respect to the fair value of derivative instruments is included in Note 13.
Gross |
| Assets |
| Liabilities |
| |||||||||
Notional | Fair | Fair |
| |||||||||||
June 30, 2021 (Millions) | Amount | Location | Value Amount | Location | Value Amount |
| ||||||||
Derivatives designated as | ||||||||||||||
hedging instruments | ||||||||||||||
Foreign currency forward/option contracts | $ | |
| Other current assets | $ | |
| Other current liabilities | $ | | ||||
Foreign currency forward/option contracts |
| |
| Other assets |
| |
| Other liabilities |
| | ||||
Interest rate contracts |
| |
| Other current assets |
| |
| Other current liabilities |
| — | ||||
Interest rate contracts |
| |
| Other assets |
| |
| Other liabilities |
| — | ||||
Total derivatives designated as hedging instruments | $ | | $ | | ||||||||||
Derivatives not designated as | ||||||||||||||
hedging instruments | ||||||||||||||
Foreign currency forward/option contracts | $ | |
| Other current assets | $ | |
| Other current liabilities | $ | | ||||
Total derivatives not designated as hedging instruments | $ | | $ | | ||||||||||
Total derivative instruments | $ | | $ | | ||||||||||
Gross |
| Assets |
| Liabilities |
| |||||||||
Notional | Fair | Fair |
| |||||||||||
December 31, 2020 (Millions) | Amount | Location | Value Amount | Location | Value Amount |
| ||||||||
Derivatives designated as | ||||||||||||||
hedging instruments | ||||||||||||||
Foreign currency forward/option contracts | $ | |
| Other current assets | $ | |
| Other current liabilities | $ | | ||||
Foreign currency forward/option contracts | | Other assets | | Other liabilities | | |||||||||
Interest rate contracts |
| |
| Other current assets |
| |
| Other current liabilities |
| — | ||||
Total derivatives designated as hedging instruments | $ | | $ | | ||||||||||
Derivatives not designated as | ||||||||||||||
hedging instruments | ||||||||||||||
Foreign currency forward/option contracts | $ | |
| Other current assets | $ | |
| Other current liabilities | $ | | ||||
Total derivatives not designated as hedging instruments | $ | | $ | | ||||||||||
Total derivative instruments | $ | | $ | | ||||||||||
Credit Risk and Offsetting of Assets and Liabilities of Derivative Instruments
The Company is exposed to credit loss in the event of nonperformance by counterparties in interest rate swaps, currency swaps, and forward and option contracts. However, the Company’s risk is limited to the fair value of the instruments. The Company actively monitors its exposure to credit risk through the use of credit approvals and credit limits, and by selecting major international banks and financial institutions as counterparties. 3M enters into master netting arrangements with counterparties when possible to mitigate credit risk in derivative transactions. A master netting arrangement may allow each counterparty to net settle amounts owed between a 3M entity and the counterparty as a result of multiple, separate derivative transactions. As of June 30, 2021, 3M has International Swaps and Derivatives Association (ISDA) agreements with
27
3M has elected to present the fair value of derivative assets and liabilities within the Company’s consolidated balance sheet on a gross basis even when derivative transactions are subject to master netting arrangements and may otherwise qualify for net presentation. However, the following tables provide information as if the Company had elected to offset the asset and liability balances of derivative instruments, netted in accordance with various criteria in the event of default or termination as stipulated by the terms of netting arrangements with each of the counterparties. For each counterparty, if netted, the Company would offset the asset and liability balances of all derivatives at the end of the reporting period based on the 3M entity that is a party to the transactions. Derivatives not subject to master netting agreements are not eligible for net presentation. As of the applicable dates presented below, no cash collateral had been received or pledged related to these derivative instruments.
Offsetting of Financial Assets under Master Netting Agreements with Derivative Counterparties
Gross Amounts not Offset in the | ||||||||||||
|
| Consolidated Balance Sheet that are |
| |||||||||
Subject to Master Netting Agreements | ||||||||||||
Gross Amount of | Gross Amount of | |||||||||||
Derivative Assets | Eligible Offsetting | |||||||||||
Presented in the | Recognized | Cash | ||||||||||
Consolidated | Derivative | Collateral | Net Amount of | |||||||||
June 30, 2021 (Millions) | Balance Sheet | Liabilities | Received | Derivative Assets | ||||||||
Derivatives subject to master netting agreements | $ | | $ | | $ | — | $ | | ||||
Derivatives not subject to master netting agreements |
| |
| | ||||||||
Total | $ | | $ | | ||||||||
December 31, 2020 (Millions) | ||||||||||||
Derivatives subject to master netting agreements | $ | | $ | | $ | — | $ | | ||||
Derivatives not subject to master netting agreements |
| — |
| — | ||||||||
Total | $ | | $ | | ||||||||
Offsetting of Financial Liabilities under Master Netting Agreements with Derivative Counterparties
Gross Amounts not Offset in the | ||||||||||||
| Gross Amount of |
| Consolidated Balance Sheet that are |
| ||||||||
Derivative | Subject to Master Netting Agreements | |||||||||||
Liabilities | Gross Amount of | |||||||||||
Presented in the | Eligible Offsetting | Cash | Net Amount of | |||||||||
Consolidated | Recognized | Collateral | Derivative | |||||||||
June 30, 2021 (Millions) | Balance Sheet | Derivative Assets | Pledged | Liabilities | ||||||||
Derivatives subject to master netting agreements | $ | | $ | | $ | — | $ | | ||||
Derivatives not subject to master netting agreements |
| — |
| — | ||||||||
Total | $ | | $ | | ||||||||
December 31, 2020 (Millions) | ||||||||||||
Derivatives subject to master netting agreements | $ | | $ | | $ | — | $ | | ||||
Derivatives not subject to master netting agreements |
| — |
| — | ||||||||
Total | $ | | $ | | ||||||||
Currency Effects
3M estimates that year-on-year foreign currency transaction effects, including hedging impacts, decreased pre-tax income by approximately $
28
NOTE 13. Fair Value Measurements
3M follows ASC 820, Fair Value Measurements and Disclosures, with respect to assets and liabilities that are measured at fair value on a recurring basis and nonrecurring basis. The Company adopted ASU No. 2018-13, Changes to the Disclosure Requirements for Fair Value Measurements, as of January 1, 2020. This ASU primarily amended the disclosures around Level 3 investments, of which the Company had an immaterial amount for all periods presented.
In addition to the information above, refer to Note 15 in 3M’s 2020 Annual Report on Form 10-K for a qualitative discussion of the assets and liabilities that are measured at fair value on a recurring and nonrecurring basis, a description of the valuation methodologies used by 3M, and categorization within the valuation framework of ASC 820.
The following tables provide information by level for assets and liabilities that are measured at fair value on a recurring basis.
Fair Value Measurements | ||||||||||||
Description | Fair Value at | Using Inputs Considered as | ||||||||||
(Millions) |
| June 30, 2021 |
| Level 1 |
| Level 2 |
| Level 3 | ||||
Assets: | ||||||||||||
Available-for-sale: | ||||||||||||
Marketable securities: | ||||||||||||
Corporate debt securities | $ | | $ | — | $ | | $ | — | ||||
Commercial paper | | — | | — | ||||||||
Certificates of deposit/time deposits |
| |
| — |
| |
| — | ||||
U.S. treasury securities |
| |
| |
| — |
| — | ||||
U.S. municipal securities |
| |
| — |
| — |
| | ||||
Derivative instruments — assets: | ||||||||||||
Foreign currency forward/option contracts |
| |
| — |
| |
| — | ||||
Interest rate contracts |
| |
| — |
| |
| — | ||||
Liabilities: | ||||||||||||
Derivative instruments — liabilities: | ||||||||||||
Foreign currency forward/option contracts |
| |
| — |
| |
| — | ||||
Fair Value Measurements | ||||||||||||
Description | Fair Value at | Using Inputs Considered as | ||||||||||
(Millions) |
| December 31, 2020 |
| Level 1 |
| Level 2 |
| Level 3 | ||||
Assets: | ||||||||||||
Available-for-sale: | ||||||||||||
Marketable securities: | ||||||||||||
Corporate debt securities | $ | | $ | — | $ | | $ | — | ||||
Commercial paper | | — | | — | ||||||||
Certificates of deposit/time deposits |
| |
| — |
| |
| — | ||||
U.S. treasury securities |
| |
| |
| — |
| — | ||||
U.S. municipal securities |
| |
| — |
| — |
| | ||||
Derivative instruments — assets: | ||||||||||||
Foreign currency forward/option contracts |
| |
| — |
| |
| — | ||||
Interest rate contracts |
| |
| — |
| |
| — | ||||
Liabilities: | ||||||||||||
Derivative instruments — liabilities: | ||||||||||||
Foreign currency forward/option contracts |
| |
| — |
| |
| — | ||||
29
The following table provides a reconciliation of the beginning and ending balances of items measured at fair value on a recurring basis in the table above that used significant unobservable inputs (level 3).
| Three months ended |
| Six months ended | |||||||||
Marketable securities — certain U.S. municipal securities only | June 30, | June 30, | ||||||||||
(Millions) | 2021 |
| 2020 | 2021 |
| 2020 | ||||||
Beginning balance | $ | | $ | | $ | | $ | | ||||
Total gains or losses: | ||||||||||||
Included in earnings |
| |
| |
| |
| | ||||
Included in other comprehensive income |
| |
| |
| |
| | ||||
Purchases and issuances |
| |
| |
| |
| | ||||
Sales and settlements |
| |
| |
| |
| ( | ||||
Transfers in and/or out of level 3 |
| |
| |
| |
| | ||||
Ending balance | $ | | $ | | $ | | $ | | ||||
Change in unrealized gains or losses for the period included in earnings for securities held at the end of the reporting period |
| — |
| — |
| — |
| — | ||||
In addition, the plan assets of 3M’s pension and postretirement benefit plans are measured at fair value on a recurring basis (at least annually). Refer to Note 13 in 3M’s 2020 Annual Report on Form 10-K.
Assets and Liabilities that are Measured at Fair Value on a Nonrecurring Basis:
Disclosures are required for certain assets and liabilities that are measured at fair value, but are recognized and disclosed at fair value on a nonrecurring basis in periods subsequent to initial recognition. For 3M, such measurements of fair value relate primarily to indefinite-lived and long-lived asset impairments, goodwill impairments, and adjustment in carrying value of equity securities for which the measurement alternative of cost less impairment plus or minus observable price changes is used. There were
Fair Value of Financial Instruments:
The Company’s financial instruments include cash and cash equivalents, marketable securities, accounts receivable, certain investments, accounts payable, borrowings, and derivative contracts. The fair values of cash equivalents, accounts receivable, accounts payable, and short-term borrowings and current portion of long-term debt approximated carrying values because of the short-term nature of these instruments. Available-for-sale marketable securities, in addition to certain derivative instruments, are recorded at fair values as indicated in the preceding disclosures. To estimate fair values (classified as level 2) for its long-term debt, the Company utilized third-party quotes, which are derived all or in part from model prices, external sources, market prices, or the third-party’s internal records. Information with respect to the carrying amounts and estimated fair values of these financial instruments follow:
June 30, 2021 | December 31, 2020 | |||||||||||
| Carrying |
| Fair |
| Carrying |
| Fair | |||||
(Millions) | Value | Value | Value | Value | ||||||||
Long-term debt, excluding current portion | $ | | $ | | $ | | $ | | ||||
The fair values reflected above consider the terms of the related debt absent the impacts of derivative/hedging activity. The carrying amount of long-term debt referenced above is impacted by certain fixed-to-floating interest rate swaps that are designated as fair value hedges and by the designation of certain fixed rate Eurobond securities issued by the Company as hedging instruments of the Company’s net investment in its European subsidiaries. A number of 3M’s fixed-rate bonds were trading at a premium at June 30, 2021 and December 31, 2020 due to the lower interest rates and tighter credit spreads compared to issuance levels.
30
NOTE 14. Commitments and Contingencies
Legal Proceedings:
The Company and some of its subsidiaries are involved in numerous claims and lawsuits, principally in the United States, and regulatory proceedings worldwide. These claims, lawsuits and proceedings include, but are not limited to, products liability (involving products that the Company now or formerly manufactured and sold), intellectual property, commercial, antitrust, federal False Claims Act, securities, and state and federal environmental laws. Unless otherwise stated, the Company is vigorously defending all such litigation and proceedings. From time to time, the Company also receives subpoenas or requests for information from various government agencies. The Company generally responds to such subpoenas and requests in a cooperative, thorough and timely manner. These responses sometimes require time and effort and can result in considerable costs being incurred by the Company. Such subpoenas and requests can also lead to the assertion of claims or the commencement of administrative, civil or criminal legal proceedings against the Company and others, as well as to settlements. The outcomes of legal proceedings and regulatory matters are often difficult to predict. Any determination that the Company’s operations or activities are not, or were not, in compliance with applicable laws or regulations could result in the imposition of fines, civil or criminal penalties, and equitable remedies, including disgorgement, suspension or debarment or injunctive relief. Additional information about the Company’s process for disclosure and recording of liabilities and insurance receivables related to legal proceedings can be found in Note 16 “Commitments and Contingencies” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020.
The following sections first describe the significant legal proceedings in which the Company is involved, and then describe the liabilities and associated insurance receivables the Company has accrued relating to its significant legal proceedings.
Respirator Mask/Asbestos Litigation
As of June 30, 2021, the Company is a named defendant, with multiple co-defendants, in numerous lawsuits in various courts that purport to represent approximately
The vast majority of the lawsuits and claims resolved by and currently pending against the Company allege use of some of the Company’s mask and respirator products and seek damages from the Company and other defendants for alleged personal injury from workplace exposures to asbestos, silica, coal mine dust or other occupational dusts found in products manufactured by other defendants or generally in the workplace. A minority of the lawsuits and claims resolved by and currently pending against the Company generally allege personal injury from occupational exposure to asbestos from products previously manufactured by the Company, which are often unspecified, as well as products manufactured by other defendants, or occasionally at Company premises.
The Company’s current volume of new and pending matters is substantially lower than it experienced at the peak of filings in 2003. The Company expects that filing of claims by unimpaired claimants in the future will continue to be at much lower levels than in the past. Accordingly, the number of claims alleging more serious injuries, including mesothelioma, other malignancies, and black lung disease, will represent a greater percentage of total claims than in the past. Over the past plus years, the Company has prevailed in
The Company has demonstrated in these past trial proceedings that its respiratory protection products are effective as claimed when used in the intended manner and in the intended circumstances. Consequently, the Company believes that claimants are unable to
31
establish that their medical conditions, even if significant, are attributable to the Company’s respiratory protection products. Nonetheless, the Company’s litigation experience indicates that claims of persons alleging more serious injuries, including mesothelioma, other malignancies, and black lung disease, are costlier to resolve than the claims of unimpaired persons, and it therefore believes the average cost of resolving pending and future claims on a per-claim basis will continue to be higher than it experienced in prior periods when the vast majority of claims were asserted by medically unimpaired claimants. In addition, during the second half of 2020 and as of June 30, 2021, the Company has experienced an increase in the number of cases filed that allege injuries from exposures to coal mine dust.
As previously reported, the State of West Virginia, through its Attorney General, filed a complaint in 2003 against the Company and
Respirator Mask/Asbestos Liabilities and Insurance Receivables
The Company regularly conducts a comprehensive legal review of its respirator mask/asbestos liabilities. The Company reviews recent and historical claims data, including without limitation, (i) the number of pending claims filed against the Company, (ii) the nature and mix of those claims (i.e., the proportion of claims asserting usage of the Company’s mask or respirator products and alleging exposure to each of asbestos, silica, coal or other occupational dusts, and claims pleading use of asbestos-containing products allegedly manufactured by the Company), (iii) the costs to defend and resolve pending claims, and (iv) trends in filing rates and in costs to defend and resolve claims, (collectively, the “Claims Data”). As part of its comprehensive legal review, the Company regularly provides the Claims Data to a third party with expertise in determining the impact of Claims Data on future filing trends and costs. The third party assists the Company in estimating the costs to defend and resolve pending and future claims. The Company uses these estimates to develop its best estimate of probable liability.
Developments may occur that could affect the Company’s estimate of its liabilities. These developments include, but are not limited to, significant changes in (i) the key assumptions underlying the Company’s accrual, including, the number of future claims, the nature and mix of those claims, the average cost of defending and resolving claims, and in maintaining trial readiness (ii) trial and appellate outcomes, (iii) the law and procedure applicable to these claims, and (iv) the financial viability of other co-defendants and insurers.
As a result of its review of its respirator mask/asbestos liabilities, of pending and expected lawsuits and of the cost of resolving claims of persons who claim more serious injuries, including mesothelioma, other malignancies, and black lung disease, the Company increased its accruals in the first six months of 2021 for respirator mask/asbestos liabilities by $
32
As of June 30, 2021, the Company’s receivable for insurance recoveries related to the respirator mask/asbestos litigation was $
Respirator Mask/Asbestos Litigation — Aearo Technologies
On April 1, 2008, a subsidiary of the Company acquired the stock of Aearo Holding Corp., the parent of Aearo Technologies (“Aearo”). Aearo manufactured and sold various products, including personal protection equipment, such as eye, ear, head, face, fall and certain respiratory protection products.
As of June 30, 2021, Aearo and/or other companies that previously owned and operated Aearo’s respirator business (American Optical Corporation, Warner-Lambert LLC, AO Corp. and Cabot Corporation (“Cabot”)) are named defendants, with multiple co-defendants, including the Company, in numerous lawsuits in various courts in which plaintiffs allege use of mask and respirator products and seek damages from Aearo and other defendants for alleged personal injury from workplace exposures to asbestos, silica-related, coal mine dust, or other occupational dusts found in products manufactured by other defendants or generally in the workplace.
As of June 30, 2021, the Company, through its Aearo subsidiary, had accruals of $
Aearo’s share of the contingent liability is further limited by an agreement entered into between Aearo and Cabot on July 11, 1995. This agreement provides that, so long as Aearo pays to Cabot a quarterly fee of $
Developments may occur that could affect the estimate of Aearo’s liabilities. These developments include, but are not limited to: (i) significant changes in the number of future claims, (ii) significant changes in the average cost of resolving claims, (iii) significant changes in the legal costs of defending these claims, (iv) significant changes in the mix and nature of claims received, (v) trial and appellate outcomes, (vi) significant changes in the law and procedure applicable to these claims, (vii) significant changes in the liability allocation among the co-defendants, (viii) the financial viability of members of the Payor Group including exhaustion of available insurance coverage limits, and/or (ix) a determination that the interpretation of the contractual obligations on which Aearo has estimated its share of liability is inaccurate. The Company cannot determine the impact of these potential developments on its current estimate of Aearo’s share of liability for these existing and future claims. If any of the developments described above were to occur, the actual amount of these liabilities for existing and future claims could be significantly larger than the amount accrued.
Because of the inherent difficulty in projecting the number of claims that have not yet been asserted, the complexity of allocating responsibility for future claims among the Payor Group, and the several possible developments that may occur that could affect the
33
estimate of Aearo’s liabilities, the Company cannot estimate the amount or range of amounts by which Aearo’s liability may exceed the accrual the Company has established.
Environmental Matters and Litigation
The Company’s operations are subject to environmental laws and regulations including those pertaining to air emissions, wastewater discharges, toxic substances, and the handling and disposal of solid and hazardous wastes enforceable by national, state, and local authorities around the world, and private parties in the United States and abroad. These laws and regulations provide, under certain circumstances, a basis for the remediation of contamination, for capital investment in pollution control equipment, for restoration of or compensation for damages to natural resources, and for personal injury and property damage claims. The Company has incurred, and will continue to incur, costs and capital expenditures in complying with these laws and regulations, defending personal injury and property damage claims, and modifying its business operations in light of its environmental responsibilities. In its effort to satisfy its environmental responsibilities and comply with environmental laws and regulations, the Company has established, and periodically updates, policies relating to environmental standards of performance for its operations worldwide.
Under certain environmental laws, including the United States Comprehensive Environmental Response, Compensation and Liability Act of 1980 (CERCLA) and similar state laws, the Company may be jointly and severally liable, typically with other companies, for the costs of remediation of environmental contamination at current or former facilities and at off-site locations. The Company has identified numerous locations, most of which are in the United States, at which it may have some liability. Please refer to the section entitled “Environmental Liabilities and Insurance Receivables” that follows for information on the amount of the accrual for such liabilities.
Environmental Matters
As previously reported, the Company has been voluntarily cooperating with ongoing reviews by local, state, federal (primarily the U.S. Environmental Protection Agency (EPA)), and international agencies of possible environmental and health effects of various perfluorinated compounds, including perfluorooctanoate (PFOA), perfluorooctane sulfonate (PFOS), perfluorohexane sulfonate (PFHxS), or other per- and polyfluoroalkyl substances (collectively PFAS). As a result of its phase-out decision in May 2000, the Company no longer manufactures certain PFAS compounds including PFOA, PFOS, PFHxS, and their pre-cursor compounds. The Company ceased manufacturing and using the vast majority of these compounds within approximately
PFAS Regulatory Activity
Regulatory activities concerning PFAS continue in the United States, Europe and elsewhere, and before certain international bodies. These activities include gathering of exposure and use information, risk assessment, and consideration of regulatory approaches. In the European Union, where 3M has manufacturing facilities in countries such as Germany and Belgium, recent regulatory activities have included both preliminary and on-going work on various restrictions under the Regulation concerning the Registration, Evaluation, Authorization and Restriction of Chemicals (REACH), including the restriction of PFAS in certain usages and a broader restriction of PFAS as a class. As of late 2020, PFOA is subject to broad restrictions under the EU’s Persistent Organic Pollutants (POPs) Regulation. Dyneon, a 3M subsidiary that operates a facility at Gendorf, Germany, has a recycling process for a critical emulsifier from which small amounts of PFOA are present after recycling, as an unintended and unavoidable byproduct of certain earlier process steps. The recycling process removes and concentrates the PFOA for incineration in accordance with applicable waste law. With respect to the applicability of the recently enacted POPs, Dyneon proactively consulted with the relevant German regulatory authority regarding process improvements underway that are designed to ensure compliance with the PFOA limits in the recycled material. The engagement is ongoing. In addition, 3M has been working with the Public Flemish Waste Agency (OVAM) for several years to investigate and remediate historical PFOA contaminations at and near its Zwijndrecht facility in Antwerp, Belgium. In connection with a ring road construction project (the Oosterweel Project) in Antwerp that has involved extensive soil work, an investigative
34
committee with judicial powers was formed in June 2021 by the Flemish Government to investigate PFOA found in the soil and groundwater near 3M’s Zwijndrecht facility. The Company testified at a Flemish parliamentary committee hearing in June 2021 on PFOA-related matters and is cooperating with the authorities in this investigation. Separately, the Company is aware that certain residents of Zwijndrecht have filed a criminal complaint with an Antwerp investigatory judge against 3M, alleging it had unlawfully abandoned waste in violation of its environmental care obligations. 3M has not been served with any such complaint.
In the United States, the EPA has developed human health effects documents summarizing the available data studies of both PFOA and PFOS. In May 2016, the EPA announced lifetime health advisory levels for PFOA and PFOS at
The U.S. Agency for Toxic Substances and Disease Registry (ATSDR) within the Department of Health and Human Services released a draft Toxicological Profile for PFAS for public review and comment in June 2018. In the draft report, ATSDR proposed draft minimal risk levels (MRLs) for PFOS, PFOA and several other PFAS. An MRL is an estimate of the daily human exposure to a hazardous substance that is likely to be without appreciable risk of adverse non-cancer health effects over a specified duration of exposure. MRLs establish a screening level and are not intended to define cleanup or action levels for ATSDR or other agencies. In May 2021, ATSDR released a final toxicological profile for certain PFAS that preserved the draft MRLs. Earlier, in April 2021, EPA released a final toxicity assessment for PFBS.
As periodically required under the Safe Drinking Water Act (SDWA), the EPA published in May 2012 a list of unregulated substances, including
In February 2019, the EPA issued a PFAS Action Plan that outlines short- and long-term actions the EPA plans to take to address PFAS – actions that include developing a national drinking water determination for PFOA and PFOS, strengthening enforcement authorities and evaluating cleanup approaches, nationwide drinking water monitoring for PFAS, expanding scientific knowledge for understanding and managing risk from PFAS, and developing consistent risk communication tools for communicating with other agencies and the public. With respect to PFOA and PFOS in groundwater, EPA issued interim recommendations in December 2019, providing guidance for screening levels and preliminary remediation goals for groundwater that is a current or potential drinking water source, to inform final clean-up levels of contaminated sites.
EPA has taken a number of actions to advance its PFAS Action Plan and regulatory agenda and to comply with mandatory actions required by Congress in the National Defense Authorization Act for Fiscal Year 2020. EPA announced in its Spring 2020 Regulatory Agenda, released in June 2020, that it intended to publish a notice of proposed rulemaking to designate PFOA and PFOS as hazardous substances under CERCLA in August 2020. In November 2020, EPA announced it was developing a new analytical method to test for PFAS in wastewater and other environmental media. In December 2020, EPA released for public comment interim guidance on destroying and disposing of certain PFAS and PFAS-containing materials. The Company submitted comments on that draft guidance document.
In March 2021, EPA published its intention to initiate a process to develop a national primary drinking water regulation for PFOA and PFOS; the process is expected to take several years and will include further analyses, scientific review and opportunities for public comment. EPA also issued an Advance Notice of Proposed Rulemaking (ANPR) in March 2021 to collect information regarding manufacturers of PFAS and the presence and treatment of PFAS in discharges from these manufacturing facilities. The Company responded to that ANPR in May 2021. EPA has also taken several actions to increase reporting and restrictions regarding PFAS under the Toxic Substances Control Act (TSCA) and the Toxics Release Inventory (TRI), which is a part of the Emergency Planning and Community Right-to-Know Act. EPA has added more than
35
manufacture (including import) or have manufactured PFAS in any year since 2011 to report information regarding PFAS uses, production volumes, disposal, exposures, and hazards. The Company plans to submit comments on the proposed rule during the public comment period, which ends in August 2021.
Several state legislatures and state agencies have been evaluating or have taken actions related to cleanup standards, groundwater values or drinking water values for PFOS, PFOA, and other PFAS, and 3M has submitted various responsive comments. Those states include the following:
Minnesota Department of Health in May 2017 stated that HBVs “are designed to reduce long-term health risks across the population and are based on multiple safety factors to protect the most vulnerable citizens, which makes them overprotective for most of the residents in our state.” As of 2021, the current HBVs are
Vermont finalized drinking water standards for a combination of PFOA, PFOS and
In October 2020, 3M and several other parties filed notices of appeal in the appellate division of the Superior Court of New Jersey to challenge the validity of the New Jersey PFOS and PFOA regulations. In January 2021, the appellate division of the court denied the group’s motion to stay the regulations, and the parties are proceeding to litigation on the merits. In March 2021, 3M filed a lawsuit against the New York State Department of Health, on the grounds that drinking water levels set by the agency for PFOS and PFOA should be vacated because they are arbitrary and did not comply with statutorily required processes. In April 2021, 3M also filed a lawsuit against the Michigan Department of Environment, Great Lakes, and Energy (EGLE) to invalidate the drinking water standards EGLE promulgated under an accelerated timeline. EGLE has moved to dismiss that lawsuit.
The Company cannot predict what additional regulatory actions in the United States, Europe and elsewhere arising from the foregoing or other proceedings and activities, if any, may be taken regarding such compounds or the consequences of any such actions to the Company.
Litigation Related to Historical PFAS Manufacturing Operations in Alabama
As previously reported, a former employee filed a putative class action lawsuit against 3M, BFI Waste Management Systems of Alabama, and others in the Circuit Court of Morgan County, Alabama (the “St. John” case), seeking property damage from exposure to certain perfluorochemicals at or near the Company’s Decatur, Alabama, manufacturing facility. The parties have agreed to continue to stay the St. John case, pending ongoing mediation between the parties involved in this case and another case discussed below.
In October 2015, West Morgan-East Lawrence Water & Sewer Authority (Water Authority) filed an individual complaint against 3M Company, Dyneon, L.L.C, and Daikin America, Inc., in the U.S. District Court for the Northern District of Alabama. The complaint also includes representative plaintiffs who brought the complaint on behalf of themselves, and a class of all owners and possessors of property who use water provided by the Water Authority and
36
fund a new water filtration system, with 3M indemnifying the Water Authority from liability resulting from the resolution of the currently pending and future lawsuits against the Water Authority alleging liability or damages related to 3M PFAS. The putative class claims brought by the representative plaintiffs who were supplied drinking water by the Water Authority (the “Lindsey” case) remain. The parties are in active discussions regarding a negotiated resolution, and the case is currently stayed.
In June 2016, the Tennessee Riverkeeper, Inc. (Riverkeeper), a non-profit corporation, filed a lawsuit in the U.S. District Court for the Northern District of Alabama against 3M; BFI Waste Systems of Alabama; the City of Decatur, Alabama; and the Municipal Utilities Board of Decatur, Morgan County, Alabama. The complaint alleges that the defendants violated the Resource Conservation and Recovery Act in connection with the disposal of certain PFAS through their ownership and operation of their respective sites. The complaint further alleges such practices may present an imminent and substantial endangerment to health and/or the environment and that Riverkeeper has suffered and will continue to suffer irreparable harm caused by defendants’ failure to abate the endangerment unless the court grants the requested relief, including declaratory and injunctive relief. This case has been stayed, pending ongoing mediation and discussions between the parties in conjunction with the St. John case.
In August 2016, a group of over
In January 2017, several hundred plaintiffs sued 3M, Dyneon and Daikin America in Lawrence and Morgan Counties, Alabama (the “Owens” case). The plaintiffs are owners of property, residents, and holders of property interests who receive their water from the West Morgan-East Lawrence Water and Sewer Authority (Water Authority). They assert common law claims for negligence, nuisance, trespass, wantonness and battery, and they seek injunctive relief and punitive damages. The plaintiffs contend that the defendants own and operate manufacturing and disposal facilities in Decatur that have released and continue to release PFOA, PFOS and related chemicals into the groundwater and surface water of their sites, resulting in discharges into the Tennessee River. The plaintiffs contend that, as a result of the alleged discharges, the water supplied by the Water Authority to the plaintiffs was, and is, contaminated with PFOA, PFOS and related chemicals at a level dangerous to humans. The court denied a motion by co-defendant Daikin to stay this case pending resolution of the St. John case, and the case is progressing through discovery. Discussions among the parties are ongoing.
In November 2017, a putative class action (the “King” case) was filed against 3M, Dyneon, Daikin America and the West Morgan-East Lawrence Water and Sewer Authority (Water Authority) in the U.S. District Court for the Northern District of Alabama. The plaintiffs are residents of Lawrence and Morgan County, Alabama who receive their water from the Water Authority and seek injunctive relief, attorneys’ fees, compensatory and punitive damages for their alleged personal injuries. The plaintiffs contend that the defendants own and operate manufacturing and disposal facilities in Decatur, Alabama that have released and continue to release PFOA, PFOS and related chemicals into the groundwater and surface water of their sites, resulting in discharges into the Tennessee River. The plaintiffs contend that, as a result of the alleged discharges, the water supplied by the Water Authority to the plaintiffs was, and is, contaminated with PFOA, PFOS and related chemicals at a level dangerous to humans. In November 2019, the King plaintiffs amended their complaint to withdraw all class allegations. Since then, the plaintiffs have added
In July 2019, 3M announced that it had initiated an investigation into the possible presence of PFAS in
37
In September 2020, the City of Guin Water Works and Sewer Board (Guin WWSB) brought a lawsuit against 3M in Alabama state court alleging that PFAS contamination in the Guin water system stems from manufacturing operations at 3M’s Guin facility and disposal activity at a nearby landfill. In this same month, Guin WWSB dismissed its lawsuit without prejudice and has been working with 3M to further investigate the presence of chemicals in the area. The parties have made progress in ongoing discussions for a negotiated resolution.
Litigation Related to Historical PFAS Manufacturing Operations in Minnesota
In July 2016, the City of Lake Elmo filed a lawsuit in the U.S. District Court for the District of Minnesota against 3M alleging that the City suffered damages from drinking water supplies contaminated with PFAS, including costs to construct alternative sources of drinking water. In April 2019, 3M and the City of Lake Elmo agreed to settle the lawsuit for less than $
State Attorneys General Litigation related to PFAS
Minnesota. In December 2010, the State of Minnesota, by its Attorney General, filed a lawsuit in Hennepin County District Court against 3M seeking damages and injunctive relief with respect to the presence of PFAS in the groundwater, surface water, fish or other aquatic life, and sediments in the state of Minnesota (the “NRD Lawsuit”). In February 2018, 3M and the State of Minnesota reached a resolution of the NRD Lawsuit. Under the terms of the settlement, 3M agreed to provide an $
In connection with the above referenced settlement, the Minnesota Pollution Control Agency and the Department of Natural Resources, as co-trustees of the Fund, released in September 2020 a conceptual drinking water supply plan for the communities in the East Metro area, seeking public comment on
New York. The State of New York, by its Attorney General, has filed
Ohio. In December 2018, the State of Ohio, by its Attorney General, filed a lawsuit in the Common Pleas Court of Lucas County, Ohio against 3M, Tyco Fire Products LP, Chemguard, Inc., Buckeye Fire Equipment Co., National Foam, Inc., and Angus Fire Armour Corp., seeking injunctive relief and compensatory and punitive damages for remediation costs and alleged injury to Ohio natural resources from AFFF manufacturers. This case was removed to federal court and transferred to the MDL.
New Jersey. In March 2019, the New Jersey Attorney General filed
38
In May 2019, the New Jersey Attorney General and NJDEP filed a lawsuit against 3M, DuPont, and
New Hampshire. In May 2019, the New Hampshire Attorney General filed
Vermont. In June 2019, the Vermont Attorney General filed
Michigan. In January 2020, the Michigan Attorney General filed a lawsuit in state court against 3M, Dyneon, DuPont, Chemours and others seeking injunctive and equitable relief and damages for alleged injury to Michigan public natural resources and its residents related to PFAS, excluding AFFF. The case was removed to federal court in March 2021 and subsequently transferred to the AFFF MDL. The state has filed a motion to remand the case to state court. In addition, in August 2020, the Michigan Attorney General filed
Guam. In September 2019, the Attorney General of Guam filed a lawsuit against 3M and other defendants relating to contamination of the territory’s drinking water supplies and other natural resources by PFAS, allegedly resulting from the use of AFFF products at several sites around the island. This lawsuit has been removed to federal court and transferred to the AFFF MDL.
Commonwealth of Northern Mariana Islands. In December 2019, the Attorney General of the Commonwealth of Northern Mariana Islands, a U.S. territory, filed a lawsuit against 3M and other defendants relating to contamination of the territory’s drinking water supplies and other natural resources by PFAS, allegedly resulting from the use of AFFF products. This lawsuit has been removed to federal court and transferred to the AFFF MDL.
Mississippi. In December 2020, the Mississippi Attorney General filed an AFFF-related PFAS lawsuit against 3M and other defendants directly with the AFFF MDL court in South Carolina. The lawsuit alleges injuries to the State’s property and natural resources purportedly caused by PFAS contamination from AFFF use and seeks both compensatory and punitive damages.
Alaska. In April 2021, the State of Alaska filed a lawsuit against 3M and other defendants, alleging damages from the release of PFAS into the environment from a variety of products, including AFFF.
In addition to the above state attorneys general actions, several other states and the District of Columbia, through their attorneys general, have announced selection processes to retain outside law firms to bring PFSA-related lawsuits against certain manufacturers including the Company. In addition, the Company is in discussions with several state attorneys general and agencies, responding to information and other requests relating to PFAS matters and exploring potential resolution of some of the matters raised.
Aqueous Film Forming Foam (AFFF) Environmental Litigation
3M manufactured and marketed AFFF for use in firefighting at airports and military bases from approximately 1963 to 2002. As of June 30, 2021,
39
3M (along with other defendants) in various state and federal courts. As further described below, a vast majority of these pending cases are in a federal Multi-District Litigation (MDL) court in South Carolina. Additional AFFF cases continue to be filed in or transferred to the MDL. The Company also continues to defend certain AFFF cases that remain in state court and be in discussions with pre-suit claimants for possible resolutions where appropriate.
In December 2018, the U.S. Judicial Panel on Multidistrict Litigation (JPML) granted motions to transfer and consolidate all AFFF cases pending in federal courts to the U.S. District Court for the District of South Carolina to be managed in an MDL proceeding to centralize pre-trial proceedings. The parties in the MDL are currently in the process of conducting discovery. An initial pool of
In June 2019, several subsidiaries of Valero Energy Corporation, an independent petroleum refiner, filed
As of June 30, 2021, the Company is aware of
Other PFAS-related Product and Environmental Litigation
3M manufactured and sold products containing various PFOA and PFOS, including Scotchgard, for several decades. Starting in 2017, 3M has been served with individual and putative class action complaints in various state and federal courts alleging, among other things, that 3M’s customers’ improper disposal of PFOA and PFOS resulted in the contamination of groundwater or surface water. The plaintiffs in these cases generally allege that 3M failed to warn its customers about the hazards of improper disposal of the product. They also generally allege that contaminated groundwater has caused various injuries, including personal injury, loss of use and enjoyment of their properties, diminished property values, investigation costs, and remediation costs. Several companies have been sued along with 3M, including Saint-Gobain Performance Plastics Corp., Honeywell International Inc. f/k/a Allied-Signal Inc. and/or AlliedSignal Laminate Systems, Inc., Wolverine World Wide Inc., Georgia-Pacific LLC, E.I. DuPont De Nemours and Co., Chemours Co., and various carpet manufacturers.
In New York, 3M is defending
40
district court. Under the agreement, 3M, Saint-Gobain and Honeywell will collectively contribute to a fixed total amount of approximately $
In Michigan,
Wolverine also filed a third-party complaint against 3M in a suit by the State of Michigan and intervenor townships that sought to compel Wolverine to investigate and address contamination associated with its historic disposal activity. 3M filed an answer and counterclaims to Wolverine’s third-party complaint in June 2019. In September and October 2019, the parties (including 3M as third-party defendant) engaged in mediation. In December 2019, the State of Michigan, the intervening townships, and Wolverine announced that they had tentatively resolved the State and townships’ claims against Wolverine in exchange for a $
3M is also a defendant, together with Georgia-Pacific as co-defendant, in a putative class action in federal court in Michigan brought by residents of Parchment, who allege that the municipal drinking water was contaminated from waste generated by a paper mill owned by Georgia-Pacific’s corporate predecessor. The defendants’ motion to dismiss certain claims in the complaint was denied in January 2021. A trial date is set for January 2022. The parties have engaged in mediation and in April 2021 reached a preliminary settlement agreement, subject to court approval, under which 3M and Georgia-Pacific would jointly pay an amount and be released from plaintiffs’ putative class action claims. 3M’s portion is not considered material. The final fairness hearing for the settlement is scheduled for September 2021. Separately, as a result of discussions among Georgia-Pacific, 3M and municipalities near Parchment, Georgia-Pacific and 3M contributed to a fund in November 2020 to provide expanded municipal water service in the area. These municipalities released 3M from claims relating to or arising out of the extension of municipal water or the alleged PFAS contamination in the area of that extension. 3M’s portion relative to the preliminary agreement and contribution above was not material.
41
In Alabama and Georgia, 3M, together with multiple co-defendants, is defending
In California, 3M and other defendants were named as defendants in an action brought in federal court by Golden State Water Company, alleging PFAS contamination of certain wells located in its water systems. 3M filed a motion to dismiss in November 2020 and in January 2021, the court granted defendants’ motion to dismiss the case for lack of personal jurisdiction. In February 2021, the plaintiffs voluntarily dismissed their action without prejudice and filed a new case in the AFFF MDL court. Separately, in December 2020, the Orange County Water District and
In Delaware, 3M, together with several co-defendants, is defending
In New Jersey, 3M is a defendant in an action brought in federal court by Middlesex Water Company, alleging PFAS contamination of its water wells. 3M’s motion to transfer the case to the AFFF MDL was denied. 3M has moved to dismiss the complaint, and the case is currently in discovery. In September 2020, 3M was named a defendant in a similar lawsuit brought by the Borough of Hopatcong. In December 2020, 3M filed a motion to dismiss the Hopatcong matter. In January 2021, 3M was named a defendant in another similar lawsuit brought by the Pequannock Township. In March 2021, 3M filed a motion to dismiss the Pequannock matter. 3M, together with several co-defendants, is also defending
In October 2018, 3M and other defendants, including DuPont and Chemours, were named in a putative class action in the U.S. District Court for the Southern District of Ohio brought by the named plaintiff, a firefighter allegedly exposed to PFAS chemicals through his use of firefighting foam, purporting to represent a putative class of all U.S. individuals with detectable levels of PFAS in their blood. The plaintiff brings claims for negligence, battery, and conspiracy and seeks injunctive relief, including an order “establishing an independent panel of scientists” to evaluate PFAS. 3M and other entities jointly filed a motion to dismiss in February 2019. In
42
September 2019, the court denied the defendants’ motion to dismiss. In February 2020, the court denied 3M’s motion to transfer the case to the AFFF MDL. Briefing on plaintiff’s class certification motion is complete.
Other PFAS-related Matters
In July 2019, the Company received a written request from the Subcommittee on Environment of the Committee on Oversight and Reform, U.S. House of Representatives, seeking certain documents and information relating to the Company’s manufacturing and distribution of PFAS products. In September 2019, a 3M representative testified before and responded to questions from the Subcommittee on Environment with respect to PFAS and the Company’s environmental stewardship initiatives. The Company continues to cooperate with the Subcommittee.
The Company continues to make progress in its work, under the supervision of state regulators, to remediate historic disposal of PFAS-containing waste associated with manufacturing operations at its Decatur, Alabama; Cottage Grove, Minnesota; and Cordova, Illinois plants.
As previously reported, the Illinois EPA in August 2014 approved a request by the Company to establish a groundwater management zone at its manufacturing facility in Cordova, Illinois, which includes ongoing pumping of impacted site groundwater, groundwater monitoring and routine reporting of results.
In Minnesota, the Company continues to work with the Minnesota Pollution Control Agency (MPCA) pursuant to the terms of the previously disclosed May 2007 Settlement Agreement and Consent Order to address the presence of certain PFAS in the soil and groundwater at former disposal sites in Washington County, Minnesota (Oakdale and Woodbury) and at the Company’s manufacturing facility at Cottage Grove, Minnesota. Under this agreement, the Company’s principal obligations include (i) evaluating releases of certain PFAS from these sites and proposing response actions; (ii) providing treatment or alternative drinking water upon identifying any level exceeding a Health Based Value (HBV) or Health Risk Limit (HRL) (i.e., the amount of a chemical in drinking water determined by the Minnesota Department of Health (MDH) to be safe for human consumption over a lifetime) for certain PFAS for which a HBV and/or HRL exists as a result of contamination from these sites; (iii) remediating identified sources of other PFAS at these sites that are not controlled by actions to remediate PFOA and PFOS; and (iv) sharing information with the MPCA about certain perfluorinated compounds. During 2008, the MPCA issued formal decisions adopting remedial options for the former disposal sites in Washington County, Minnesota (Oakdale and Woodbury). In August 2009, the MPCA issued a formal decision adopting remedial options for the Company’s Cottage Grove manufacturing facility. During the spring and summer of 2010, 3M began implementing the agreed upon remedial options at the Cottage Grove and Woodbury sites. 3M commenced the remedial option at the Oakdale site in late 2010. At each location the remedial options were recommended by the Company and approved by the MPCA. Remediation work has been completed at the Oakdale and Woodbury sites, and they are in an operational maintenance mode. Remediation work has been substantially completed at the Cottage Grove site, with operational and maintenance activities ongoing.
In Alabama, as previously reported, the Company entered into a voluntary remedial action agreement with the Alabama Department of Environmental Management (ADEM) to remediate the presence of PFAS in the soil and groundwater at the Company’s manufacturing facility in Decatur, Alabama associated with the historic (1978-1998) incorporation of wastewater treatment plant sludge. With ADEM’s agreement, 3M substantially completed installation of a multilayer cap on the former sludge incorporation areas. Further remediation activities, including certain on-site and off-site investigations and studies, will be conducted in accordance with the July 2020 Interim Consent Order described below.
The Company operates under a 2009 consent order issued under the federal Toxic Substances Control Act (TSCA) (the “2009 TSCA consent order”) for the manufacture and use of
43
The Company is authorized to discharge wastewater from its Decatur plant pursuant to the terms of a Clean Water Act National Pollutant Discharge Elimination System (NPDES) permit issued by ADEM. The NPDES permit requires the Company to report on a monthly and quarterly basis the quality and quantity of pollutants discharged to the Tennessee River. In June 2019, the Company voluntarily disclosed to the EPA and ADEM that it had included incorrect values in certain of its monthly and quarterly reports. The Company has submitted the corrected values to both the EPA and ADEM.
As part of ongoing work with the EPA and ADEM to address compliance matters at the Decatur facility, the Company discovered it had not fully characterized its PFAS discharge in its NPDES permit. In September 2019, the Company disclosed the matter to the EPA and ADEM and announced that it had elected to temporarily idle certain other manufacturing processes at 3M Decatur. The Company is reviewing its operations at the plant, has installed wastewater treatment controls and has restarted idled processes.
As a result of the Company’s discussions with ADEM to address these and other related matters in the state of Alabama, 3M and ADEM have agreed to the terms of an interim Consent Order in July 2020 to cover all PFAS-related wastewater discharges and air emissions from the Company’s Decatur facility. Under the interim Consent Order, the Company’s principal obligations include commitments related to (i) future ongoing site operations such as (a) providing certain notices or reports and performing various analytical and characterization studies and (b) future capital improvements; and (ii) remediation activities, including certain on-site and off-site investigations and studies. Obligations related to ongoing future site operations under the Consent Order will involve additional operating costs and capital expenditures over multiple years. The Company does not expect them to have a material impact on its consolidated results of operations or financial position. With respect to remediation activities, financial obligations related to certain activities under the Consent Order are probable and reasonably estimable, and are included in the Company’s accruals for “other environmental liabilities” as described in the “Environmental Liabilities and Insurance Receivables” section below. As offsite investigation activities continue, additional remediation amounts may become probable and reasonably estimable in the future.
In December 2019, the Company received a grand jury subpoena from the U.S. Attorney’s Office for the Northern District of Alabama for documents related to, among other matters, the Company’s compliance with the 2009 TSCA consent order and unpermitted discharges to the Tennessee River. The Company is cooperating with this and other inquiries and is producing documents in response to requests.
In addition, as part of its ongoing evaluation of regulatory compliance at its Cordova, Illinois facility, the Company discovered it had not fully characterized its PFAS discharge in its NPDES permit for the Cordova facility. In November 2019, the Company disclosed this matter to the EPA, and in January 2020 disclosed this matter to the Illinois Environmental Protection Agency (IEPA). The Company continues to work with the EPA and IEPA to address these issues from the Cordova facility.
The Company is also reviewing operations at its other plants with similar manufacturing processes, such as the plant in Cottage Grove, Minnesota, to ensure those operations are in compliance with applicable environmental regulatory requirements and Company policies and procedures. As a result of these reviews, the Company discovered it had not fully characterized its PFAS discharge in its NPDES permit for the Cottage Grove facility. In March 2020, the Company disclosed this matter to the Minnesota Pollution Control Agency (MPCA) and the EPA. In July 2020, the Company received an information request from MPCA for documents and information related to, among other matters, the Company’s compliance with the Clean Water Act at its Cottage Grove facility. The Company is cooperating with this inquiry and is producing documents and information in response to the request for information. The Company continues to work with the MPCA and EPA to address the discharges from the Cottage Grove facility.
Separately, in June 2020, the Company reported to EPA and MPCA that it had not fully complied with elements of the inspection, characterization and waste stream profile verification process of the Waste and Feedstream Analysis Plan (WAP/FAP) of its Resource Conservation and Recovery Act (RCRA) permit for its Cottage Grove incinerator. In July 2020, the Company received an information request from MPCA related to the June 2020 disclosure, to which the Company responded in September 2020. The Company continues to work with the MPCA to address WAP/FAP implementation issues disclosed in June 2020. In January 2021, the Company received a notice of violation (NOV) from MPCA related to, among other matters, the above-described Clean Water Act and RCRA issues. The Company is cooperating with MPCA to address the issues that are the subject of the NOV.
In February 2020, the Company received an information request from EPA for documents and information related to, among other matters, the Company’s compliance with the Clean Water Act at its facilities that manufacture, process and use PFAS, including the Decatur, Cordova and Cottage Grove facilities. The Company is cooperating with this inquiry and is producing documents and information in response to the request for information.
44
The Company will continue to work with relevant federal and state agencies (including EPA, the U.S. Department of Justice, state environmental agencies and state attorneys general) as it conducts these reviews. The Company cannot predict at this time the outcomes of resolving these compliance matters or what potential actions may be taken by the regulatory agencies.
Other Environmental Litigation
In July 2018, the Company, along with more than
For environmental matters and litigation described above, unless otherwise described below,
Environmental Liabilities and Insurance Receivables
The Company periodically examines whether the contingent liabilities related to the environmental matters and litigation described above are probable and reasonably estimable based on experience and developments in those matters. During the first six months ended June 30, 2021, as a result of recent developments in ongoing environmental matters and litigation, the Company increased its accrual for PFAS-related other environmental liabilities by $
Recent related accrual history includes the following: During the first quarter of 2019, EPA issued its PFAS Action Plan and the Company settled the litigation with the Water Authority (both matters are described in more detail above). As previously disclosed, the Company increased its accrual for “other environmental liabilities” by $
As of June 30, 2021, the Company had recorded liabilities of $
It is difficult to estimate the cost of environmental compliance and remediation given the uncertainties regarding the interpretation and enforcement of applicable environmental laws and regulations, the extent of environmental contamination and the existence of alternative cleanup methods. Developments may occur that could affect the Company’s current assessment, including, but not limited to: (i) changes in the information available regarding the environmental impact of the Company’s operations and products; (ii) changes in environmental regulations, changes in permissible levels of specific compounds in drinking water sources, or changes in enforcement theories and policies, including efforts to recover natural resource damages; (iii) new and evolving analytical and remediation techniques; (iv) success in allocating liability to other potentially responsible parties; and (v) the financial viability of
45
other potentially responsible parties and third-party indemnitors. For sites included in both “environmental remediation liabilities” and “other environmental liabilities,” at which remediation activity is largely complete and remaining activity relates primarily to operation and maintenance of the remedy, including required post-remediation monitoring, the Company believes the exposure to loss in excess of the amount accrued would not be material to the Company’s consolidated results of operations or financial condition. However, for locations at which remediation activity is largely ongoing, the Company cannot estimate a possible loss or range of possible loss in excess of the associated established accruals for the reasons described above.
The Company has both pre-1986 general and product liability occurrence coverage and post-1985 occurrence reported product liability and other environmental coverage for environmental matters and litigation. As of June 30, 2021, the Company’s receivable for insurance recoveries related to the environmental matters and litigation was $
Product Liability Litigation
Aearo Technologies sold Dual-Ended Combat Arms – Version 2 earplugs starting in about 2003. 3M acquired Aearo Technologies in 2008 and sold these earplugs from 2008 through 2015, when the product was discontinued. In December 2018, a military veteran filed an individual lawsuit against 3M in the San Bernardino Superior Court in California alleging that he sustained personal injuries while serving in the military caused by 3M’s Dual-Ended Combat Arms earplugs – Version 2. The plaintiff asserts claims of product liability and fraudulent misrepresentation and concealment. The plaintiff seeks various damages, including medical and related expenses, loss of income, and punitive damages.
As of June 30, 2021, the Company is a named defendant in approximately
3M is also defending lawsuits brought by non-military plaintiffs in state court in Hennepin County, Minnesota. 3M removed these actions to federal court and the federal court remanded them to state court in March 2020. The Company has appealed the remand orders to the U.S. Court of Appeals for the Eighth Circuit. Oral argument on the first remand order appeal occurred in June 2021. There are approximately
46
As of June 30, 2021, the Company was a named defendant in
As previously disclosed, 3M had been a named defendant in lawsuits in federal courts involving over
The U.S. Judicial Panel on Multidistrict Litigation (JPML) consolidated all cases pending in federal courts to the U.S. District Court for the District of Minnesota to be managed in a multi-district litigation (MDL) proceeding. In July 2019, the court excluded several of the plaintiffs’ causation experts, and granted summary judgment for 3M in all cases pending at that time in the MDL. Plaintiffs have appealed that decision to the U.S. Court of Appeals for the Eighth Circuit. Plaintiffs have also appealed a 2018 jury verdict in favor of 3M in the first bellwether trial in the MDL and appealed the dismissal of another bellwether case. The Eighth Circuit court heard oral argument on all pending appeals in March 2021.
Among the
As previously disclosed, 3M had been named a defendant in
In June 2016, the Company was served with a putative class action filed in the Ontario Superior Court of Justice for all Canadian residents who underwent various joint arthroplasty, cardiovascular, and other surgeries and later developed surgical site infections that the representative plaintiff claims was due to the use of the Bair Hugger™ patient warming system. The representative plaintiff seeks relief (including punitive damages) under Canadian law based on theories similar to those asserted in the MDL.
For product liability litigation matters described in this section for which a liability has been recorded, the amount recorded is not material to the Company’s consolidated results of operations or financial condition. In addition, the Company is not able to estimate a possible loss or range of possible loss in excess of the established accruals at this time.
Stockholder Litigation
In July 2019, Heavy & General Laborers’ Locals 472 & 172 Welfare Fund filed a putative securities class action against 3M Company, its former Chairman and CEO, current Chairman and CEO, and former CFO in the U.S. District Court for the District of New Jersey. In August 2019, an individual plaintiff filed a similar putative securities class action in the same district. Plaintiffs allege that defendants made false and misleading statements regarding 3M's exposure to liability associated with PFAS, and bring claims for damages under Section 10(b) of the Securities Exchange Act of 1934 and SEC Rule 10b-5 against all defendants, and under Section 20(a) of the Securities and Exchange Act of 1934 against the individual defendants. In October 2019, the court consolidated the securities class actions and appointed a group of lead plaintiffs. In January 2020, the defendants filed a motion to transfer venue to the
47
U.S. District Court for the District of Minnesota. In August 2020, the court denied the motion to transfer venue, and in September 2020, the defendants filed a petition for writ of mandamus to the U.S. Court of Appeals for the Third Circuit. In November 2020, the federal Court of Appeals granted 3M’s petition for a writ of mandamus and directed the New Jersey federal court to transfer the action to the Minnesota federal court. The defendants filed a motion to dismiss the action in January 2021; that motion was argued in July 2021. The suit is in the early stages of litigation.
In October 2019, a stockholder derivative lawsuit was filed in the U.S. District Court for the District of New Jersey against 3M and several of its current and former executives and directors. In November and December 2019,
In August 2020, a stockholder who had previously submitted a books and records demand filed an additional follow-on derivative lawsuit in the U.S. District Court for the District of New Jersey against 3M and several of its current and former executives and directors. This derivative lawsuit, having been transferred to Minnesota federal court, also relies on similar factual allegations as the putative securities class action discussed above. In February 2021, an additional stockholder derivative lawsuit was filed in the District of Minnesota, making similar factual allegations as the putative securities class action discussed above.
Federal False Claims Act / Qui Tam Litigation
In October 2019, 3M acquired Acelity, Inc. and its KCI subsidiaries, including Kinetic Concepts, Inc. and KCI USA, Inc. As previously disclosed in the SEC filings by the KCI entities, in 2009, Kinetic Concepts, Inc. received a subpoena from the U.S. Department of Health and Human Services Office of Inspector General. In 2011, following the completion of the government’s review and its decision declining to intervene in
The government inquiry followed
In October 2016, the KCI Defendants filed counterclaims in the Godecke case, asserting breach of contract and conversion. In August 2017, the relator-plaintiff’s fraud claim in the Godecke case was dismissed in favor of the KCI defendants. In January 2018, the district court stayed the retaliation claim and the KCI Defendants' counterclaims pending the relator-plaintiff’s appeal. In September 2019, the U.S. Court of Appeals for the Ninth Circuit reversed and remanded the case to the district court for further proceedings. In April 2021, the court allowed the parties to issue subpoenas to the Centers for Medicare & Medicaid Services and its contractors, but the court has not ordered further discovery to commence. Separately, in June 2019, following discovery, the district court in the second case (the “Hartpence case”) entered summary judgment in the KCI Defendants’ favor on all of the relator-plaintiff’s claims. The relator-plaintiff then filed an appeal in the U.S. Court of Appeals for the Ninth Circuit. Oral argument in the Hartpence case was held in July 2020. The appellate court’s opinion remains pending.
For the matters described in this section for which a liability has been recorded, the amount recorded is not material to the Company’s consolidated results of operations or financial condition.
Compliance Matter
The Company, through its internal processes, discovered certain travel activities and related funding and record keeping issues raising concerns, arising from marketing efforts by certain business groups based in China. The Company initiated an internal investigation to determine whether the expenditures may have violated the U.S. Foreign Corrupt Practices Act (FCPA) or other potentially applicable anti-corruption laws. The Company has retained outside counsel and a forensic accounting firm to assist with the investigation. In July
48
2019, the Company voluntarily disclosed this investigation to both the Department of Justice and Securities and Exchange Commission and is cooperating with both agencies. The Company cannot predict at this time the outcome of its investigation or what potential actions may be taken by the Department of Justice or Securities and Exchange Commission.
NOTE 15. Stock-Based Compensation
At the May 2021 Annual Meeting, the shareholders approved the Amended and Restated 3M Company 2016 Long-Term Incentive Plan (LTIP), which included an increase of
The Company’s annual stock option and restricted stock unit grant is made in February to provide a strong and immediate link between the performance of individuals during the preceding year and the size of their annual stock compensation grants. The grant to eligible employees uses the closing stock price on the grant date. Accounting rules require recognition of expense under a non-substantive vesting period approach, requiring compensation expense recognition when an employee is eligible to retire. Employees are considered eligible to retire at age
In addition to the annual grants, the Company makes other minor grants of stock options, restricted stock units and other stock-based grants. The Company issues cash settled restricted stock units and stock appreciation rights in certain countries. These grants do not result in the issuance of common stock and are considered immaterial by the Company.
Amounts recognized in the financial statements with respect to stock-based compensation programs, which include stock options, restricted stock, restricted stock units, performance shares and the General Employees’ Stock Purchase Plan (GESPP), are provided in the following table. Capitalized stock-based compensation amounts were not material for the three and six months ended June 30, 2021 and 2020.
Stock-Based Compensation Expense
Three months ended | Six months ended |
| |||||||||||
June 30, | June 30, | ||||||||||||
(Millions) |
| 2021 |
| 2020 |
| 2021 |
| 2020 |
| ||||
Cost of sales | $ | | $ | | $ | | $ | | |||||
Selling, general and administrative expenses |
| |
| |
| |
| | |||||
Research, development and related expenses |
| |
| |
| |
| | |||||
Stock-based compensation expenses | $ | | $ | | $ | | $ | | |||||
Income tax benefits | ( | ( | ( | ( | |||||||||
Stock-based compensation expenses (benefits), net of tax | $ | | $ | | $ | | $ | | |||||
49
Stock Option Program
The following table summarizes stock option activity during the six months ended June 30, 2021:
Weighted | ||||||||||
Average | ||||||||||
| Weighted |
| Remaining |
| Aggregate | |||||
Number of | Average | Contractual | Intrinsic Value | |||||||
(Options in thousands) | Options | Exercise Price | Life (months) | (millions) | ||||||
Under option — | ||||||||||
January 1 | | $ | |
|
| |||||
Granted | |
| |
|
|
| ||||
Exercised | ( |
| |
|
|
| ||||
Forfeited | ( |
| |
|
|
| ||||
June 30 | | $ | |
| $ | |
| |||
Options exercisable | ||||||||||
June 30 | | $ | |
| $ | |
| |||
Stock options vest over a period from
For the primary 2021 annual stock option grant, the weighted average fair value at the date of grant was calculated using the Black-Scholes option-pricing model and the assumptions that follow.
Stock Option Assumptions
Annual | ||||
| 2021 | |||
Exercise price | $ | | ||
Risk-free interest rate |
| | % | |
Dividend yield |
| | % | |
Expected volatility |
| | % | |
Expected life (months) |
| |||
Black-Scholes fair value | $ | | ||
Expected volatility is a statistical measure of the amount by which a stock price is expected to fluctuate during a period. For the 2021 annual grant date, the Company estimated the expected volatility based upon the following three volatilities of 3M stock: the median of the term of the expected life rolling volatility; the median of the most recent term of the expected life volatility; and the implied volatility on the grant date. The expected term assumption is based on the weighted average of historical grants.
50
Restricted Stock and Restricted Stock Units
The following table summarizes restricted stock and restricted stock unit activity during the six months ended June 30, 2021:
| ||||||
|
|
| Weighted |
| ||
Average |
| |||||
Number of | Grant Date |
| ||||
(Shares in thousands) | Shares | Fair Value |
| |||
Nonvested balance — | ||||||
As of January 1 |
| | $ | | ||
Granted |
| |
| | ||
Vested |
| ( |
| | ||
Forfeited |
| ( |
| | ||
As of June 30 |
| | $ | | ||
As of June 30, 2021, there was $
Restricted stock units granted generally vest
Performance Shares
Instead of restricted stock units, the Company makes annual grants of performance shares to members of its executive management. The 2021 performance criteria for these performance shares (organic volume growth, return on invested capital, free cash flow conversion, and earnings per share growth) were selected because the Company believes that they are important drivers of long-term stockholder value. The number of shares of 3M common stock that could actually be delivered at the end of the performance period may be anywhere from
51
The following table summarizes performance share activity during the six months ended June 30, 2021:
| |||||
|
| Weighted |
| ||
Average |
| ||||
Number of | Grant Date |
| |||
(Shares in thousands) | Shares | Fair Value |
| ||
Undistributed balance — | |||||
As of January 1 | | $ | | ||
Granted | |
| | ||
Distributed | ( |
| | ||
Performance change | |
| | ||
Forfeited | ( |
| | ||
As of June 30 | | $ | | ||
As of June 30, 2021, there was $
NOTE 16. Business Segments
3M’s businesses are organized, managed and internally grouped into segments based on differences in markets, products, technologies and services. 3M manages its operations in
3M discloses business segment operating income as its measure of segment profit/loss, reconciled to both total 3M operating income and income before taxes. Business segment operating income includes dual credit for certain related operating income (as described below in “Elimination of Dual Credit”). Business segment operating income excludes certain expenses and income that are not allocated to business segments (as described below in “Corporate and Unallocated”). Additionally, the following special items are excluded from business segment operating income and, instead, are included within Corporate and Unallocated: significant litigation-related charges/benefits, gain/loss on sale of businesses (see Note 3), and divestiture-related restructuring actions (see Note 5).
Effective in the first quarter of 2021, the measure of segment operating performance used by 3M’s CODM changed and, as a result, 3M’s disclosed measure of segment profit/loss (business segment operating income) was updated. The change to business segment operating income aligns with the update to how the CODM assesses performance and allocates resources for the Company’s business segments. The change included the following:
Changes in cost attribution
The extent of allocation and method of attribution of certain net costs were updated to result in fewer items remaining in Corporate and Unallocated and, instead, including them in 3M’s business segments’ operating performance. See the updated description of Corporate and Unallocated below. Previously, a larger portion of ongoing corporate staff costs and costs associated with centrally managed material resource centers was retained in Corporate and Unallocated. In addition, portions of pension costs and costs associated with certain centrally managed but ongoing business-related legal matters, along with certain insurance-related costs, were retained in Corporate and Unallocated.
52
Continued alignment of customer account activity
As part of 3M’s regular customer-focus initiatives, the Company realigned certain customer account activity (“sales district”) to correlate with the primary divisional product offerings in various countries and reduce complexity for customers when interacting with multiple 3M businesses. This impacted the amount of dual credit certain business segments receive as a result of sales district attribution.
Also effective in the first quarter of 2021, within 3M’s Consumer business segment, certain safety products formerly within the Construction and Home Improvement Division and the Stationery and Office Division were moved to the newly-named Consumer Health and Safety Division (formerly the Consumer Health Care Division).
The financial information presented herein reflects the impact of the preceding changes for all periods presented.
Business Segment Information
Three months ended | Six months ended | |||||||||||
(Millions) | June 30, | June 30, | ||||||||||
Net Sales |
| 2021 |
| 2020 |
| 2021 |
| 2020 | ||||
Safety and Industrial |
| $ | |
| $ | |
| $ | |
| $ | |
Transportation and Electronics |
| |
| |
| |
| | ||||
Health Care |
| |
| |
| |
| | ||||
Consumer |
| |
| |
| |
| | ||||
Corporate and Unallocated |
| |
| |
| ( |
| | ||||
Elimination of Dual Credit |
| ( |
| ( |
| ( |
| ( | ||||
Total Company |
| $ | |
| $ | |
| $ | |
| $ | |
Operating Performance | ||||||||||||
Safety and Industrial |
| $ | |
| $ | |
| $ | |
| $ | |
Transportation and Electronics |
| |
| |
| |
| | ||||
Health Care |
| |
| |
| |
| | ||||
Consumer |
| |
| |
| |
| | ||||
Elimination of Dual Credit |
| ( |
| ( |
| ( |
| ( | ||||
Total business segment operating income |
| $ | |
| $ | |
| $ | |
| $ | |
Corporate and Unallocated | ||||||||||||
Special items: | ||||||||||||
Significant litigation-related (charges)/benefits | — | — | — | ( | ||||||||
Gain/(loss) on sale of businesses | — | | — | | ||||||||
Divestiture-related restructuring actions | — | ( | — | ( | ||||||||
Other corporate expense - net |
| ( |
| ( |
| ( |
| ( | ||||
Total Corporate and Unallocated | ( | | ( | | ||||||||
Total Company operating income | $ | | $ | | $ | | $ | | ||||
Other expense/(income), net | $ | | $ | | $ | | $ | | ||||
Income before income taxes | $ | | $ | | $ | | $ | | ||||
Corporate and Unallocated
Corporate and Unallocated operating income includes “special items” and “other corporate expense-net”. Special items include significant litigation-related charges/benefits, gain/loss on sale of businesses, and divestiture-related restructuring costs. Other corporate expense-net includes items such as net costs related to limited unallocated corporate staff and centrally managed material resource centers of expertise costs, certain litigation and environmental expenses largely related to legacy products/businesses not allocated to business segments, corporate philanthropic activity, and other net costs that 3M may choose not to allocate directly to its business segments. Other corporate expense-net also includes costs and income from contract manufacturing, transition services and other arrangements with the acquirer of the Communication Markets Division following its 2018 divestiture through 2019 and the
53
acquirer of the former Drug Delivery business following its 2020 divestiture. Items classified as revenue from this activity are included in Corporate and Unallocated net sales. Because Corporate and Unallocated includes a variety of miscellaneous items, it is subject to fluctuation on a quarterly and annual basis.
Elimination of Dual Credit
3M business segment reporting measures include dual credit to business segments for certain sales and related operating income. Management evaluates each of its
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.
Management’s Discussion and Analysis of Financial Condition and Results of Operations (MD&A) is designed to provide a reader of 3M’s financial statements with a narrative from the perspective of management. 3M’s MD&A is presented in the following sections:
| ● | Overview |
| ● | Results of Operations |
| ● | Performance by Business Segment |
| ● | Financial Condition and Liquidity |
| ● | Cautionary Note Concerning Factors That May Affect Future Results |
Forward-looking statements in Part I, Item 2 may involve risks and uncertainties that could cause results to differ materially from those projected (refer to the section entitled “Cautionary Note Concerning Factors That May Affect Future Results” in Part I, Item 2 and the risk factors provided in Part II, Item 1A for discussion of these risks and uncertainties).
OVERVIEW
3M is a diversified global manufacturer, technology innovator and marketer of a wide variety of products and services. Effective in the first quarter of 2021, 3M made the following changes. Information provided herein reflects the impact of these changes for all periods presented.
| ● | Change in accounting principle for net periodic pension and postretirement plan cost. See detailed discussion in Note 1. |
| ● | Change in measure of segment operating performance used by 3M’s chief operating decision maker—impacting 3M’s disclosed measure of segment profit/loss (business segment operating income). See additional information in Note 16. |
| ● | Change in alignment of certain products within 3M’s Consumer business segment—creating the Consumer Health and Safety Division. See additional information in Note 16. |
3M manages its operations in four operating business segments: Safety and Industrial; Transportation and Electronics; Health Care; and Consumer. From a geographic perspective, any references to EMEA refer to Europe, Middle East and Africa on a combined basis.
Consideration of COVID-19:
As described in the Overview—Consideration of COVID-19 section of Part II, Item 7 of the Company’s 2020 Annual Report on Form 10-K, 3M is impacted by the global pandemic and related effects associated with the coronavirus (COVID-19). In addition, risk factors with respect to COVID-19, can be found in Item 1A “Risk Factors” in this Quarterly Report on Form 10-Q. Given the diversity
54
of 3M’s businesses, some of the factors described in that Overview—Consideration of COVID-19 section have increased the demand for 3M products, while others have decreased demand or made it more difficult for 3M to serve customers.
Overall, 3M experienced broad-based growth across all business segments and geographic areas in the second quarter of 2021, benefiting from continued improvements in certain end markets including home improvement, oral care and industrial along with healthcare elective procedure volumes increasing as COVID-19 related hospitalizations declined. 3M’s total sales increased 24.7% and 16.7% year-on-year in the second quarter and first six months of 2021, respectively. Organic local-currency sales increased 21.4% and 14.3% year-on-year in the second quarter and first six months of 2021, respectively. 3M experienced the strongest sales growth in Transportation and Electronics and Health Care. While COVID-related respirator sales increased year-on-year in the second quarter and first six months of 2021, they are estimated to have negatively impacted year-on-year second quarter organic local-currency sales growth by approximately 1 percent as they grew at a slower rate than the rest of the Company. For the first six months of 2021, they positively impacted year-on-year organic-local currency sales growth by approximately 1 percent. In the second quarter of 2020, as effects of COVID-19 set-in, weak demand in a number of end markets negatively impacted oral care, automotive and aerospace, automotive aftermarket, commercial solutions, stationery and office, and businesses aligned to general industrial applications such as industrial adhesives and tapes and abrasives. At the same time, 2020 demand was increasing in areas such as personal safety, home improvement, general cleaning, semiconductor, data center, and biopharma filtration.
3M’s operating income margins decreased 2.3 percentage points year-on-year in the second quarter and remained flat the first six months of 2021. Factoring out the impact on operating income of special items as described in the Certain amounts adjusted for special items - (non-GAAP measures) section below, operating income margins increased 2.4 and 2.1 percentage points to 22.0 and 22.3 percent for the second quarter and first six months of 2021, respectively, when compared to 2020. Various COVID-19 implications contributed in part to these results.
Overall, the impact of the COVID-19 pandemic on 3M’s consolidated results of operations was primarily driven by factors related to changes in demand for products and disruption in global supply chains as described or referenced above. While it is not feasible to identify or quantify all the other direct and indirect implications on 3M’s results of operations, below are factors that 3M believes have also affected its result for second quarter and first six months of 2021 when compared to 2020:
Factors contributing to charges or other impacts:
| ● | Increased raw materials and logistics costs during the first half of 2021 from ongoing COVID-19 related supply chain challenges further magnified in February 2021 by winter storm Uri in the United States. |
| ● | Period expenses of unabsorbed manufacturing costs and increased expected credit losses on customer receivables in the second quarter of 2020. |
| ● | Restructuring actions addressing structural enterprise costs and operations in certain end markets as a result of the COVID-19 pandemic and related economic impact resulting in a second quarter 2020 charge of $58 million. |
| ● | Committed financial support in the second quarter of 2020 to various COVID-relief and medical research initiatives. |
| ● | Charge of $22 million in the first quarter of 2020 related to equity securities as discussed in the “Assets and Liabilities that are Measured at Fair Value on a Nonrecurring Basis” section of Note 13 that use the measurement alternative described therein in addition to an immaterial pre-tax charge related to impairment of certain indefinite lived tradenames. |
Factors providing benefits or other impacts:
| ● | In 2020 ongoing cost management in discretionary spending in areas such as travel, professional services, and advertising/merchandising resulting in lower spending. |
| ● | Continued productivity efforts, including year-on-year savings from restructuring actions taken in 2020 |
| ● | Government-sponsored COVID-response stimulus and relief initiatives in 2020, including certain employee retention benefits under the Coronavirus Aid, Relief and Economic Security (CARES) Act in the United States. |
| ● | Lower incentive compensation and self-insured medical visit/insurance expense in 2020. |
| ● | Accelerated vacation usage policies in the second quarter of 2020 which benefited the second quarter of 2020, but provided a penalty in the second half of 2020. |
Refer to the Financial Condition and Liquidity section below for more information on the Company’s liquidity position.
55
Due to the speed with which the COVID-19 situation continues to develop and evolve and the uncertainty of its duration and the timing of recovery, 3M is not able at this time to predict the extent to which the COVID-19 pandemic may have a material effect on its consolidated results of operations or financial condition.
Operating income margin and earnings per share attributable to 3M common shareholders – diluted:
The following table provides the increases (decreases) in operating income margins and diluted earnings per share for the three and six months ended June 30, 2021 and 2020.
Three months ended | Six months ended | |||||||||||
June 30, 2021 | June 30, 2021 | |||||||||||
Percent of | Earnings per | Percent of | Earnings per | |||||||||
net sales | diluted share | net sales | diluted share | |||||||||
Same period last year | 24.3 | % | $ | 2.25 | 22.3 | % | $ | 4.50 | ||||
Significant litigation-related charges/benefits | — | — | 0.1 | (0.07) | ||||||||
Gain/loss on sale of businesses | (5.4) | (0.52) | (2.6) | (0.52) | ||||||||
Divestiture-related restructuring actions | 0.7 | 0.08 | 0.4 | 0.08 | ||||||||
Same period last year, excluding special items | 19.6 | % | $ | 1.81 | 20.2 | % | $ | 3.99 | ||||
Increase/(decrease) due to: | ||||||||||||
Organic growth/productivity and other | 4.1 | 0.89 | 2.8 | 1.23 | ||||||||
Selling price and raw material impact | (1.4) | (0.17) | (0.8) | (0.17) | ||||||||
Acquisitions/divestitures | (0.1) | (0.02) | — | (0.05) | ||||||||
Foreign exchange impacts | (0.2) | 0.08 | 0.1 | 0.21 | ||||||||
Other expense (income), net | N/A | 0.06 | N/A | 0.09 | ||||||||
Income tax rate | N/A | (0.03) | N/A | 0.12 | ||||||||
Shares of common stock outstanding | N/A | (0.03) | N/A | (0.06) | ||||||||
Current period, excluding special items | 22.0 | % | $ | 2.59 | 22.3 | % | $ | 5.36 | ||||
None | — | — | — | — | ||||||||
Current period | 22.0 | % | $ | 2.59 | 22.3 | % | $ | 5.36 | ||||
Operating income margins decreased 2.3 percentage points in the second quarter of 2021 and remained flat for the first six months of 2021 when compared to the same period last year. For the second quarter of 2021, net income attributable to 3M was $1.5 billion, or $2.59 per diluted share compared to $1.3 billion or $2.25 per diluted share in the same period last year, an increase of 15.1 percent on a per diluted share basis. For the first six months of 2021 net income attributable to 3M was $3.1 billion, or $5.36 per diluted share compared to $2.6 billion or $4.50 per diluted share in the same period last year, an increase of 19.1 percent on a per diluted share basis.
The Company refers to various amounts or measures on an “adjusted basis”. These exclude special items. These non-GAAP measures are further described and reconciled to the most directly comparable GAAP financial measures in the Certain amounts adjusted for special items - (non-GAAP measures) section below.
On an adjusted basis, operating margins increased 2.4 percentage points to 22.0 percent in the second quarter of 2021 when compared to the same period last year. For the first six months of 2021, operating margins increased 2.1 percentage points to 22.3 percent when compared to the same period last year. Net income attributable to 3M was $1.5 billion, or $2.59 per diluted share versus $1.0 billion, or $1.81 per diluted share in the same period last year, which was an increase of 43.5 percent on a per diluted share basis. On an adjusted basis for the first six months of 2021, net income attributable to 3M was $3.1 billion, or $5.36 per diluted share versus $2.3 billion, or $3.99 per diluted share for the same period last year, which was an increase of 34.4 percent on a per diluted share basis.
56
Additional discussion related to the components of the year-on-year change in earnings per diluted share follows:
Organic growth/productivity and other:
| ● | Higher organic volume growth, ongoing cost management, and improved productivity increased operating income margins and earnings per diluted share year-on-year for both the second quarter and first six months of 2021. The following also impacted results: |
| o | Second quarter of 2021 benefit of $91 million pre-tax ($0.12 per share after tax) from a favorable Brazilian Supreme Court decision that concluded on the impact of state value-added tax when determining Brazil’s federal sales-based social tax—essentially lowering the social tax that 3M should have paid in prior periods. |
| o | Certain increased legal and reserve adjustments costs year-over-year. 3M regularly reviews and updates its associated liabilities and is involved in various trials and defense preparation as discussed in Note 14. |
| o | 2021 benefit from restructuring actions taken in 2020 and positive/negative impact of year-over-year change in non-divestiture-related restructuring charges, net of adjustments, for respective periods. Note 5 provides additional information relative to restructuring actions. |
| o | COVID-impacts recognized on certain assets in the first quarter of 2020. |
| o | On a combined basis, higher defined benefit pension and postretirement service cost expense year-on-year. |
Selling price and raw material impact:
| ● | Higher raw material and logistics costs from strong end-market demand and COVID-impacted manufacturing and supply chain disruptions that were further magnified by February 2021 winter storm Uri in the U.S. These factors were partially offset by higher selling prices for both the second quarter and first six months of 2021. |
Acquisitions/divestitures:
| ● | Divestiture impacts are comprised of the lost income from the divestiture of the Company’s drug delivery business (sale completed in May 2020). |
Foreign exchange impacts:
| ● | Foreign currency impacts (net of hedging) increased operating income by approximately $49 million and $139 million (or pre-tax earnings by approximately $60 million and $155 million) year-on-year for the second quarter and first six months of 2021, respectively. This estimate includes the effect of translating profits from local currencies into U.S. dollars; the impact of currency fluctuations on the transfer of goods between 3M operations in the United States and abroad; and transaction gains and losses, including derivative instruments designed to reduce foreign currency exchange rate risks. |
Other expense (income), net:
| ● | Higher income related to non-service cost components of pension and postretirement expense, decreased expense year-on-year for both the second quarter and first six months of 2021. |
| ● | Interest expense (net of interest income) decreased slightly for the second quarter of 2021 and remained flat for the first six months of 2021 compared to the same periods year-on-year. |
Income tax rate:
| ● | Certain items above reflect specific income tax rates associated therewith. Overall, the effective tax rate for the second quarter and first six months of 2021 was 21.5 percent and 18.9 percent, respectively, largely consistent with 21.0 percent and 19.3 percent for the same periods, respectively, in prior year. |
| ● | On an adjusted basis, the effective tax rate for the second quarter and first six months of 2021 was 21.5 percent and 18.9 percent, respectively, an increase of 0.8 and decrease of 1.8 percentage points compared to the same periods year-on-year. |
Shares of common stock outstanding:
| ● | Higher shares outstanding decreased earnings per share year-on-year for both the second quarter and first six months of 2021. |
Certain amounts adjusted for special items - (non-GAAP measures):
In addition to reporting financial results in accordance with U.S. GAAP, the Company also provides non-GAAP measures that adjust for the impacts of special items. For the periods presented, special items include the items described below. Operating income (measure of segment operating performance), income before taxes, net income, earnings per share, and the effective tax rate are all
57
measures for which 3M provides the reported GAAP measure and a measure adjusted for special items. The adjusted measures are not in accordance with, nor are they a substitute for, GAAP measures. The Company considers these non-GAAP measures in evaluating and managing the Company’s operations. The Company believes that discussion of results adjusted for these items is meaningful to investors as it provides a useful analysis of ongoing underlying operating trends. The determination of these items may not be comparable to similarly titled measures used by other companies. Special items include:
Significant litigation-related charges/benefits:
| ● | In the first quarter of 2020, 3M recorded a net pre-tax charge of $17 million ($13 million after tax) related to PFAS (certain perfluorinated compounds) matters. The charge was more than offset by a reduction in tax expense of $52 million related to resolution of tax treatment with authorities regarding the previously disclosed 2018 agreement reached with the State of Minnesota that resolved the Natural Resources Damages (NRD) lawsuit. These items, in aggregate, resulted in a $39 million after tax benefit. |
Gain/loss on sale of businesses:
| ● | In the first quarter of 2020, 3M recorded a pre-tax gain of $2 million ($1 million loss after tax) related to the sale of its advanced ballistic-protection business and recognition of certain contingent consideration. In the second quarter of 2020, 3M recorded a pre-tax gain of $387 million ($304 million after tax) related to the sale of its drug delivery business. Refer to Note 3 for further details. |
Divestiture-related restructuring actions:
| ● | In the second quarter 2020, following the divestiture of substantially all of the drug delivery business management approved and committed to undertake certain restructuring actions addressing corporate functional costs and manufacturing footprint across 3M in relation to the magnitude of amounts previously allocated/burdened to the divested business. As a result, 3M recorded a pre-tax charge of $55 million ($46 million after tax). Refer to Note 5 for further details. |
58
(Dollars in millions, except per share amounts) | Operating Income | Operating Income Margin | Income Before Taxes | Provision for Income Taxes | Effective Tax Rate | Net Income Attributable to 3M | Earnings Per Diluted Share | Earnings per diluted share percent change | ||||||||||||||||
Three months ended June 30, 2020 GAAP | $ | 1,740 | 24.3 | % | $ | 1,650 | $ | 347 | 21.0 | % | $ | 1,306 | $ | 2.25 | ||||||||||
Adjustments for special items: | ||||||||||||||||||||||||
Gain/loss on sale of businesses | (387) | (387) | (83) | (304) | (0.52) | |||||||||||||||||||
Divestiture-related restructuring actions | 55 | 55 | 9 | 46 | 0.08 | |||||||||||||||||||
Three months ended June 30, 2020 adjusted amounts (non-GAAP measures) | $ | 1,408 | 19.6 | % | $ | 1,318 | $ | 273 | 20.7 | % | $ | 1,048 | $ | 1.81 | ||||||||||
| ||||||||||||||||||||||||
Three months ended June 30, 2021 GAAP |
| $ | 1,971 | 22.0 | % | $ | 1,938 | $ | 415 | 21.5 | % | $ | 1,524 | $ | 2.59 | 15.1 | % | |||||||
Adjustments for special items: | ||||||||||||||||||||||||
None | ||||||||||||||||||||||||
Three months ended June 30, 2021 adjusted amounts (non-GAAP measures) |
| $ | 1,971 | 22.0 | % | $ | 1,938 | $ | 415 | 21.5 | % | $ | 1,524 | $ | 2.59 | 43.5 | % | |||||||
(Dollars in millions, except per share amounts) | Operating Income | Operating Income Margin | Income Before Taxes | Provision for Income Taxes | Effective Tax Rate | Net Income Attributable to 3M | Earnings Per Diluted Share | Earnings per diluted share percent change | ||||||||||||||||
Six months ended June 30, 2020 GAAP | $ | 3,403 | 22.3 | % | $ | 3,238 | $ | 625 | 19.3 | % | $ | 2,614 | $ | 4.50 | ||||||||||
Adjustments for special items: | ||||||||||||||||||||||||
Significant litigation-related charges/benefits | 17 | 17 | 56 | (39) | (0.07) | |||||||||||||||||||
Gain/loss on sale of businesses | (389) | (389) | (86) | (303) | (0.52) | |||||||||||||||||||
Divestiture-related restructuring actions | 55 | 55 | 9 | 46 | 0.08 | |||||||||||||||||||
Six months ended June 30, 2020 adjusted amounts (non-GAAP measures) | $ | 3,086 | 20.2 | % | $ | 2,921 | $ | 604 | 20.7 | % | $ | 2,318 | $ | 3.99 | ||||||||||
| ||||||||||||||||||||||||
Six months ended June 30, 2021 GAAP |
| $ | 3,965 | 22.3 | % | $ | 3,883 | $ | 734 | 18.9 | % | $ | 3,148 | $ | 5.36 | 19.1 | % | |||||||
Adjustments for special items: | ||||||||||||||||||||||||
None | — | — | — | — | — | |||||||||||||||||||
Six months ended June 30, 2021 adjusted amounts (non-GAAP measures) |
| $ | 3,965 | 22.3 | % | $ | 3,883 | $ | 734 | 18.9 | % | $ | 3,148 | $ | 5.36 | 34.4 | % |
59
Sales and operating income by business segment:
The following tables contain sales and operating income results by business segment for the three and six months ended June 30, 2021 and 2020. Refer to the section entitled “Performance by Business Segment” later in MD&A for additional discussion concerning 2021 versus 2020 results, including Corporate and Unallocated. Refer to Note 16 for additional information on business segments, including Elimination of Dual Credit.
Three months ended June 30, |
| ||||||||||||||||||
2021 | 2020 | % change | |||||||||||||||||
| Net |
| Oper. |
| Net | Oper. | Net | Oper. | |||||||||||
(Dollars in millions) | Sales | Income | Sales | Income | Sales | Income | |||||||||||||
Business Segments | |||||||||||||||||||
Safety and Industrial | $ | 3,254 |
| $ | 718 | $ | 2,657 |
| $ | 623 |
| 22.4 | % | 15.3 | % | ||||
Transportation and Electronics |
| 2,482 |
|
| 546 |
| 1,937 |
|
| 360 |
| 28.1 | 51.6 | ||||||
Health Care |
| 2,278 |
|
| 576 |
| 1,823 |
|
| 301 |
| 24.9 | 91.9 | ||||||
Consumer |
| 1,482 |
|
| 311 |
| 1,231 |
|
| 278 |
| 20.4 | 11.8 | ||||||
Corporate and Unallocated |
| 1 |
|
| (42) |
| 1 |
|
| 297 |
| — | — | ||||||
Elimination of Dual Credit |
| (547) |
|
| (138) |
| (473) |
|
| (119) |
| — | — | ||||||
Total Company | $ | 8,950 |
| $ | 1,971 | $ | 7,176 |
| $ | 1,740 |
| 24.7 | % | 13.2 | % | ||||
Six months ended June 30, |
| ||||||||||||||||||
2021 | 2020 | % change |
| ||||||||||||||||
| Net |
| Oper. |
| Net |
| Oper. |
| Net |
| Oper. |
| |||||||
(Dollars in millions) | Sales | Income | Sales | Income | Sales | Income |
| ||||||||||||
Business Segments | |||||||||||||||||||
Safety and Industrial | $ | 6,581 |
| $ | 1,529 | $ | 5,584 |
| $ | 1,317 |
| 17.8 | % | 16.1 | % | ||||
Transportation and Electronics |
| 5,013 |
|
| 1,137 |
| 4,176 |
|
| 824 |
| 20.0 | 38.0 | ||||||
Health Care |
| 4,526 |
|
| 1,085 |
| 3,927 |
|
| 753 |
| 15.2 | 44.2 | ||||||
Consumer |
| 2,855 |
|
| 600 |
| 2,481 |
|
| 543 |
| 15.1 | 10.6 | ||||||
Corporate and Unallocated |
| (1) |
|
| (89) |
| 1 |
|
| 198 |
| — | — | ||||||
Elimination of Dual Credit |
| (1,173) |
|
| (297) |
| (918) |
|
| (232) |
| — | — | ||||||
Total Company | $ | 17,801 |
| $ | 3,965 | $ | 15,251 |
| $ | 3,403 |
| 16.7 | % | 16.5 | % | ||||
Three months ended June 30, 2021 |
| ||||||||||
Worldwide Sales Change | Organic local- | Total sales |
| ||||||||
By Business Segment | currency sales | Acquisitions | Divestitures | Translation | change |
| |||||
Safety and Industrial |
| 17.6 | % | — | % | — | % | 4.8 | % | 22.4 | % |
Transportation and Electronics |
| 24.2 | — | — | 3.9 | 28.1 | |||||
Health Care |
| 23.2 | — | (2.6) | 4.3 | 24.9 | |||||
Consumer |
| 17.8 | — | — | 2.6 | 20.4 | |||||
Total Company |
| 21.4 | % | — | % | (0.7) | % | 4.0 | % | 24.7 | % |
Six months ended June 30, 2021 |
| ||||||||||
Worldwide Sales Change | Organic local- | Total sales |
| ||||||||
By Business Segment | currency sales | Acquisitions | Divestitures | Translation | change |
| |||||
Safety and Industrial |
| 13.7 | % | — | % | — | % | 4.1 | % | 17.8 | % |
Transportation and Electronics |
| 16.4 | — | — | 3.6 | 20.0 | |||||
Health Care |
| 15.8 | — | (4.3) | 3.7 | 15.2 | |||||
Consumer |
| 12.8 | — | — | 2.3 | 15.1 | |||||
Total Company |
| 14.3 | % | — | % | (1.1) | % | 3.5 | % | 16.7 | % |
60
Sales by geographic area:
Percent change information compares the second quarter and first six months of 2021 with the same period last year, unless otherwise indicated. Additional discussion of business segment results is provided in the Performance by Business Segment section.
Three months ended June 30, 2021 |
| |||||||||||||||
Europe, |
| |||||||||||||||
Asia | Middle East | Other |
| |||||||||||||
| Americas |
| Pacific |
| & Africa |
| Unallocated |
| Worldwide |
| ||||||
Net sales (millions) |
| $ | 4,582 |
| $ | 2,655 |
| $ | 1,714 |
| $ | (1) |
| $ | 8,950 | |
% of worldwide sales |
| 51.2 | % |
| 29.7 | % |
| 19.1 | % |
| — |
| 100.0 | % | ||
Components of net sales change: | ||||||||||||||||
Volume — organic |
| 25.3 | % |
| 15.9 | % |
| 19.8 | % |
| — |
| 21.3 | % | ||
Price |
| 0.3 |
| (0.5) |
| 0.3 |
| — |
| 0.1 | ||||||
Organic local-currency sales |
| 25.6 |
| 15.4 |
| 20.1 |
| — |
| 21.4 | ||||||
Acquisitions |
| — |
| — |
| — |
| — |
| — | ||||||
Divestitures |
| (0.7) |
| — |
| (1.6) |
| — |
| (0.7) | ||||||
Translation |
| 1.2 |
| 4.8 |
| 10.2 |
| — |
| 4.0 | ||||||
Total sales change |
| 26.1 | % |
| 20.2 | % |
| 28.7 | % |
| — |
| 24.7 | % | ||
Total sales change: | ||||||||||||||||
Safety and Industrial | 22.3 | % | 25.5 | % | 19.7 | % | — | 22.4 | % | |||||||
Transportation and Electronics | 34.9 | % | 20.1 | % | 50.5 | % | — | 28.1 | % | |||||||
Health Care | 24.0 | % | 20.2 | % | 31.8 | % | — | 24.9 | % | |||||||
Consumer | 20.8 | % | 13.6 | % | 29.6 | % | — | 20.4 | % | |||||||
Organic local-currency sales change: | ||||||||||||||||
Safety and Industrial | 20.8 | % | 18.4 | % | 10.2 | % | — | 17.6 | % | |||||||
Transportation and Electronics | 33.8 | % | 16.7 | % | 38.8 | % | — | 24.2 | % | |||||||
Health Care | 25.3 | % | 13.8 | % | 26.4 | % | — | 23.2 | % | |||||||
Consumer | 19.7 | % | 8.7 | % | 19.2 | % | — | 17.8 | % | |||||||
Additional information beyond what is included in the preceding table is as follows:
| ● | In the Americas geographic area, U.S. total sales increased 21 percent and organic-local currency sales increased 22 percent. Total sales in Mexico increased 66 percent and organic local-currency sales increased 60 percent. In Canada, total sales increased 52 percent and organic local-currency sales increased of 37 percent. In Brazil, total sales increased 58 percent and organic local-currency sales increased 54 percent. |
| ● | In the Asia Pacific geographic area, China total sales increased 20 percent and organic local-currency sales increased 12 percent. In Japan, total sales increased 10 percent and organic local-currency sales increased 12 percent. |
61
Six months ended June 30, 2021 |
| |||||||||||||||
Europe, |
| |||||||||||||||
Asia | Middle East | Other |
| |||||||||||||
| Americas |
| Pacific |
| & Africa |
| Unallocated |
| Worldwide |
| ||||||
Net sales (millions) |
| $ | 8,910 |
| $ | 5,424 |
| $ | 3,469 |
| $ | (2) |
| $ | 17,801 | |
% of worldwide sales |
| 50.0 | % |
| 30.5 | % |
| 19.5 | % |
| — |
| 100.0 | % | ||
Components of net sales change: | ||||||||||||||||
Volume — organic |
| 14.5 | % |
| 14.5 | % |
| 11.4 | % |
| — |
| 13.9 | % | ||
Price |
| 0.8 |
| (0.5) |
| 0.7 |
| — |
| 0.4 | ||||||
Organic local-currency sales |
| 15.3 |
| 14.0 |
| 12.1 |
| — |
| 14.3 | ||||||
Acquisitions |
| — |
| — |
| — |
| — |
| — | ||||||
Divestitures |
| (1.2) |
| — |
| (2.4) |
| — |
| (1.1) | ||||||
Translation |
| 0.5 |
| 5.1 |
| 9.0 |
| — |
| 3.5 | ||||||
Total sales change |
| 14.6 | % |
| 19.1 | % |
| 18.7 | % |
| — |
| 16.7 | % | ||